UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
	 
	FORM 8-K
	 
	CURRENT REPORT
	PURSUANT TO SECTION 13 OR 15(d)
	OF THE SECURITIES EXCHANGE ACT OF 1934
	 
	Date of Report (Date of earliest event reported): October 16,
	2017
	 
	 
	MABVAX THERAPEUTICS HOLDINGS, INC.
	(Exact name of registrant as specified in its charter)
	 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
| 
 
	Delaware
 
 | 
 
	 
 
 | 
 
	000-31265
 
 | 
 
	 
 
 | 
 
	93-0987903
 
 | 
| 
 
	(State or
	other jurisdiction
	of
	incorporation)
 
	 
 
 | 
 
	 
 
 | 
 
	(Commission
	File
	Number)
 
	 
 
 | 
 
	 
 
 | 
 
	(IRS Employer
	Identification
	No.)
 
	 
 
 | 
 
	 
	11535 Sorrento Valley Rd., Suite 400
	San Diego, CA 92121
	(Address of principal executive offices and zip code)
	 
	Registrant’s telephone number, including area code:
	(858) 259-9405
	 
	N/A
	(Former name or former address, if changed since last
	report.)
	 
	 
	Check the appropriate box below if the Form 8-K filing is intended
	to simultaneously satisfy the filing obligation of the registrant
	under any of the following provisions:
	 
| 
 
	☐
 
 | 
 
	Written communications pursuant to Rule 425 under the Securities
	Act (17 CFR 230.425)
 
 | 
 
	 
| 
 
	☐
 
 | 
 
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act
	(17 CFR 240.14a-12)
 
 | 
 
	 
| 
 
	☐
 
 | 
 
	Pre-commencement communications pursuant to Rule 14d-2(b) under the
	Exchange Act (17 CFR 240.14d-2(b))
 
 | 
 
	 
| 
 
	☐
 
 | 
 
	Pre-commencement communications pursuant to Rule 13e-4(c) under the
	Exchange Act (17 CFR 240.13e-4(c))
 
 | 
 
	 
	Indicate by check mark whether the registrant is an emerging growth
	company as defined in as defined in Rule 405 of the Securities Act
	of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
	Securities Exchange Act of 1934 (§240.12b-2 of this
	chapter).
	 
	Emerging growth company [X]
	 
	If an emerging growth company, indicate by check mark if the
	registrant has elected not to use the extended transition period
	for complying with any new or revised financial accounting
	standards provided pursuant to Section 13(a) of the Exchange Act. [
	]
	 
	 
	 
	Item
	1.01
	Entry
	into a Material Definitive Agreement.
 
 
	 
	On
	October 18, 2017, MabVax Therapeutics Holdings, Inc. (the
	Company”) entered into exchange agreements (each, an
	“Exchange Agreement” and collectively, the
	“Exchange Agreements”) with the holders of all of the
	Company’s outstanding shares of Series F Convertible
	Preferred Stock (the “Series F Preferred Stock”),
	Series G Convertible Preferred Stock (the “Series G Preferred
	Stock”) and Series H Convertible Preferred Stock (the
	“Series H Preferred Stock”), pursuant to which 665,281
	shares of Series F Preferred Stock, 1,000,000 shares of Series G
	Preferred Stock and 850 shares of Series H Preferred Stock were
	exchanged for an aggregate of 58,000 newly authorized shares of
	Series L Convertible Preferred Stock (the “Series L Preferred
	Stock”).
	In
	connection with the transaction we agreed to hold a special meeting
	of stockholders to approve the issuance of common stock upon
	conversion of the Series L Preferred Stock.
	 
	The
	terms of the Exchange Agreements and Series L Preferred Stock were
	determined by arms-length negotiation between the parties. No
	commission or other payment was received by the Company in
	connection with the Exchange Agreements. Such exchange was
	conducted pursuant to the exemption provided by
	Section 3(a)(9) of the Securities Act of 1933, as amended (the
	“Securities Act”), and Series L Preferred Stock
	issuable pursuant to the Exchange Agreements and the Conversion
	Shares will be issued in reliance on the exemption from
	registration contained in Section 3(a)(9) of the Securities
	Act.
	 
	Pursuant
	to a registration rights agreement entered into between the Company
	and the Holders on October 18, 2017 (the “Registration Rights
	Agreement”), the Company agreed to use its reasonable best
	efforts to file a registration statement registering the Conversion
	Shares for resale within ten days of closing and cause the
	registration statement to be declared effective within 30 days of
	filing.
	 
	The
	foregoing description of the Exchange Agreement and Registration
	Rights Agreement is not complete and is qualified in its entirety
	by reference to the full text of the form of Exchange Agreement and
	form of Registration Rights Agreement, copies of which are filed as
	Exhibits 10.1 and 10.2 to this report, respectively, and are
	incorporated herein by reference.
	 
	Item
	3.02
	Unregistered
	Sales of Equity Securities.
 
 
	 
	The
	information set forth in Item 1.01 is incorporated herein by
	reference.
	 
	Item
	5.03
	Amendments
	to Articles of Incorporation or Bylaws; Change in Fiscal
	Year.
 
 
	 
	On October 16, 2017, the Company filed a Certificate of
	Designations, Preferences and Rights of the 0% Series L Convertible
	Preferred Stock
	(the
	"Certificate of Designation")
	with the Delaware
	Secretary of State, designating 58,000 shares of preferred stock as
	Series L Preferred Stock.
	On
	October 18, 2017, the Company filed a Certificate of Correction to
	the Certificate of Designation to include a sentence that was
	inadvertently omitted.
	 
	The shares of Series L Preferred Stock are convertible into shares
	of common stock based on a conversion calculation equal to the
	stated value of the Series L Preferred Stock, plus all accrued and
	unpaid dividends (the “Base Amount”), if any, on such
	Series L Preferred Stock, as of such date of determination, divided
	by the conversion price. The stated value of each share of Series L
	Preferred Stock is $100 and the initial conversion price is $0.60
	per share, each subject to adjustment for stock splits, stock
	dividends, recapitalizations, combinations, subdivisions or other
	similar events.
	 
	The holders of Series L Preferred Stock will be entitled to receive
	dividends if and when declared by our board of directors. The
	Series L Preferred Stock shall participate on an “as
	converted” basis, with all dividends declared on our common
	stock.  In addition, if the Company grants, issues or
	sells any rights to purchase its securities pro rata to all record
	holders of common stock, each holder will be entitled to acquire
	such securities applicable to the granted purchase rights as if the
	holder had held the number of shares of common stock acquirable
	upon complete conversion of all Series L Preferred Stock then
	held.
	 
	 
	We are prohibited from effecting a conversion of the Series L
	Preferred Stock
	if the Company has
	not obtained stockholder approval for the full conversion of the
	Series L Preferred Stock in accordance with the rules of the Nasdaq
	Stock Market LLC ("Nasdaq") or
	to the extent that, as a result of such
	conversion, the holder would beneficially own more than 4.99% of
	the number of shares of common stock outstanding immediately after
	giving effect to the issuance of shares of common stock upon
	conversion of the Series L Preferred Stock, which beneficial
	ownership limitation may be increased by the holder up to, but not
	exceeding, 9.99%. Each holder is entitled to vote on all matters
	submitted to stockholders of the Company, and shall have the number
	of votes equal to the number of shares of common stock issuable
	upon conversion of such holder’s Series L Preferred
	Stock,
	substituting the consolidated closing bid price of
	the common stock on October 13, 2017, for the then-applicable
	conversion price, and
	not in excess of
	the beneficial ownership limitations or limitations required by the
	rules and regulations of Nasdaq.
	 
	 
	 
	 
	 
	Holders
	of Series L Preferred Stock will be entitled to a preferential
	payment of cash per share equal to the greater of 100% of the Base
	Amount on the date of payment or the amount per share had the
	holders converted such preferred shares immediately prior to the
	date of payment upon the liquidation, dissolution or winding up of
	the affairs of the Company, or a consolidation or merger of the
	Company with or into any other corporation or corporations, or a
	sale of all or substantially all of the assets of the Company, or
	the effectuation by the Company of a transaction or series of
	transactions in which more than 50% of the voting shares of the
	Company is disposed of or conveyed.
	 
	The
	foregoing description of the Certificate of Designation is not
	complete and is qualified in its entirety by reference to the full
	text of the Certificate of Designation and Certificate of
	Correction, copies of which are filed as Exhibits 3.1 and 3.2 to
	this report, respectively, and are incorporated herein by
	reference.
	 
	Item
	9.01
	Financial
	Statements and Exhibits
 
 
	 
	(d)
	Exhibits.
	 
| 
 
	Exhibit No.
 
 | 
 
	 
 
 | 
 
	Description
 
 | 
| 
 | 
 
	 
 
 | 
 
	Certificate
	of Designations of Preferences, Rights and Limitations of Series L
	Convertible Preferred Stock
 
 | 
| 
 | 
 
	 
 
 | 
 
	Certificate of Correction to the Certificate of Designations of
	Preferences, Rights and Limitations of Series L Convertible
	Preferred Stock
 
 | 
| 
 | 
 
	 
 
 | 
 
	Form of
	Exchange Agreement
 
 | 
| 
 | 
 
	 
 
 | 
 
	Form of
	Registration Rights Agreement
 
 | 
 
	  
	 
	 
	 
	 
	SIGNATURES
	 
	Pursuant to the requirements of the Securities Exchange Act of
	1934, the registrant has duly caused this report to be signed on
	its behalf by the undersigned hereunto duly
	authorized.
	 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	MABVAX THERAPEUTICS HOLDINGS, INC.
 
 | 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
| 
 
	Dated: October 19, 2017
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	/s/ Gregory P. Hanson
 
 | 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	Gregory P. Hanson
 
 | 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	Chief Financial Officer
 
 | 
 
	 
	 
	 
	 
	 
	 
	Exhibit 3.1
	 
	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF
	THE
	0% SERIES L CONVERTIBLE PREFERRED STOCK OF
	MABVAX THERAPEUTICS HOLDINGS, INC.
	 
	I, J.
	David Hansen, hereby certify that I am the President and Chief
	Executive Officer of MabVax Therapeutics Holdings, Inc. (the
	“
	Company
	”), a
	corporation organized and existing under the Delaware General
	Corporation Law (the “
	DGCL
	”), and further do hereby
	certify:
	 
	That
	pursuant to the authority expressly conferred upon the Board of
	Directors of the Company (the “
	Board
	”) by the Company’s
	Certificate of Incorporation, as amended (the “
	Certificate of Incorporation
	”),
	the Board on October 16, 2017, adopted the following resolutions
	creating a series of shares of Preferred Stock designated as 0%
	Series L Convertible Preferred Stock, none of which shares have
	been issued, which, following filing of this Certificate of
	Designations with the Secretary of State of the State of Delaware,
	this Certificate of Designations shall be effective as of October
	16, 2017:
	 
	RESOLVED, that the
	Board designates the 0% Series L Convertible Preferred Stock and
	the number of shares constituting such series, and fixes the
	rights, powers, preferences, privileges and restrictions relating
	to such series in addition to any set forth in the Certificate of
	Incorporation as follows:
	 
	TERMS OF SERIES L CONVERTIBLE PREFERRED STOCK
	 
	1.
	 
	Designation
	and Number of Shares
	. There shall hereby be created and
	established a series of preferred stock of the Company designated
	as “0% Series L Convertible Preferred Stock” (the
	“
	Preferred
	Shares
	”). The authorized number of Preferred Shares
	shall be 58,000 shares
	. Each Preferred
	Share shall have $0.01 par value (the “
	Par Value
	”). Capitalized terms not defined herein
	shall have the meaning as set forth in Section
	23
	below.
	 
	2.
	 
	Ranking
	.
	The rights of all such shares of capital stock of the Company (the
	“
	Junior Stock
	”),
	other than the Series A Preferred Stock, Series B Preferred Stock,
	Series C Preferred Stock, Series D Preferred Stock, Series E
	Preferred Stock, Series J Preferred Stock and Series K Preferred
	Stock, shall be subject to the rights, powers, preferences and
	privileges of the Preferred Shares. In the event of the merger or
	consolidation of the Company with or into another corporation, the
	Preferred Shares shall maintain their relative rights, powers,
	designations, privileges and preferences provided for herein and no
	such merger or consolidation shall result inconsistent
	therewith.
 
	 
	3.
	 
	Dividends
	. In addition to
	Sections 5(a) and 11 below, from and after the first date of
	issuance of any Preferred Shares (the “
	Initial Issuance Date
	”), each
	holder of a Preferred Share (each, a “
	Holder
	” and collectively, the
	“
	Holders
	”) shall
	be entitled to receive dividends (“
	Dividends
	”) when and as declared
	by the Board, from time to time, in its sole discretion, which
	Dividends shall be paid by the Company out of funds legally
	available therefor, payable, subject to the conditions and other
	terms hereof, in cash as if such Holders had converted the
	Preferred Shares into Common Stock (without regard to any
	limitations on conversion) and had held such shares of Common Stock
	on the record date for such dividends and distributions. Payments
	under the preceding sentence shall be made concurrently with the
	dividend or distribution to the holders of Common
	Stock.
	 
	4.
	 
	Conversion
	. Each Preferred
	Share shall be convertible into validly issued, fully paid and
	non-assessable shares of Common Stock (as defined below) on the
	terms and conditions set forth in this Section 4.
 
	 
	 
	 
	(a)
	 
	Holder’s Conversion
	Right
	. Subject to the provisions of Section 4(e), at any
	time or times on or after the Initial Issuance Date, each Holder
	shall be entitled to convert any whole number of Preferred Shares
	into validly issued, fully paid and non-assessable shares of Common
	Stock in accordance with Section 4(c) at the Conversion Rate (as
	defined below).
	 
	(b)
	 
	Conversion Rate
	. The number of
	validly issued, fully paid and non-assessable shares of Common
	Stock issuable upon conversion of each Preferred Share pursuant to
	Section 4(a) shall be determined according to the following formula
	(the “
	Conversion
	Rate
	”):
	 
	Base Amount
	Conversion
	Price
	 
	No
	fractional shares of Common Stock are to be issued upon the
	conversion of any Preferred Shares. If the issuance would result in
	the issuance of a fraction of a share of Common Stock, the Company
	shall round such fraction of a share of Common Stock up to the
	nearest whole share.
	 
	(c)
	 
	Mechanics of Conversion
	. The
	conversion of each Preferred Share shall be conducted in the
	following manner:
 
	 
	(i)
	 
	Holder’s Conversion
	. To
	convert a Preferred Share into validly issued, fully paid and
	non-assessable shares of Common Stock on any date (a
	“
	Conversion
	Date
	”), a Holder shall deliver (whether via facsimile
	or otherwise), for receipt on or prior to 11:59 p.m., New York
	time, on such date, a copy of an executed notice of conversion of
	the share(s) of Preferred Shares subject to such conversion in the
	form attached hereto as
	Exhibit I
	(the “
	Conversion
	Notice
	”) to the Company. If required by Section
	4(c)(vi), within five (5) Trading Days following a conversion of
	any such Preferred Shares as aforesaid, such Holder shall surrender
	to a nationally recognized overnight delivery service for delivery
	to the Company the original certificates representing the share(s)
	of Preferred Shares (the “
	Preferred Share Certificates
	”) so
	converted as aforesaid.
	 
	(ii)
	 
	Company’s
	Response
	. On or before the first (1
	st
	) Trading Day
	following the date of receipt of a Conversion Notice, the Company
	shall transmit by facsimile an acknowledgment of confirmation, in
	the form attached hereto as
	Exhibit II
	,
	of receipt of such Conversion Notice to such Holder and the
	Transfer Agent, which confirmation shall constitute an instruction
	to the Transfer Agent to process such Conversion Notice in
	accordance with the terms herein. On or before the second
	(2
	nd
	)
	Trading Day following the date of receipt by the Company of such
	Conversion Notice, the Company shall (1) provided that the Transfer
	Agent is participating in DTC Fast Automated Securities Transfer
	Program, credit such aggregate number of shares of Common Stock to
	which such Holder shall be entitled to such Holder’s or its
	designee’s balance account with DTC through its
	Deposit/Withdrawal at Custodian system, or (2) if the Transfer
	Agent is not participating in the DTC Fast Automated Securities
	Transfer Program, issue and deliver (via reputable overnight
	courier) to the address as specified in such Conversion Notice, a
	certificate, registered in the name of such Holder or its designee,
	for the number of shares of Common Stock to which such Holder shall
	be entitled. If the number of Preferred Shares represented by the
	Preferred Share Certificate(s) submitted for conversion pursuant to
	Section 4(c)(vi) is greater than the number of Preferred Shares
	being converted, then the Company shall if requested by such
	Holder, as soon as practicable and in no event later than three (3)
	Trading Days after receipt of the Preferred Share Certificate(s)
	and at its own expense, issue and deliver to such Holder (or its
	designee) a new Preferred Share Certificate representing the number
	of Preferred Shares not converted.
	 
	 
	 
	(iii)
	 
	Record
	Holder
	. The Person or Persons entitled to receive the shares
	of Common Stock issuable upon a conversion of Preferred Shares
	shall be treated for all purposes as the record holder or holders
	of such shares of Common Stock on the Conversion Date.
	 
	(iv)
	 
	Company’s
	Failure to Timely Convert
	. If the Company shall fail, for
	any reason or for no reason, to issue to a Holder within three (3)
	Trading Days after the Company’s receipt of a Conversion
	Notice (whether via facsimile or otherwise) (the
	“
	Share Delivery
	Deadline
	”), a certificate for the number of shares of
	Common Stock to which such Holder is entitled and register such
	shares of Common Stock on the Company’s share register or to
	credit such Holder’s or its designee’s balance account
	with DTC for such number of shares of Common Stock to which such
	Holder is entitled upon such Holder’s conversion of any
	Preferred Shares (as the case may be) (a “
	Conversion Failure
	”), then, in
	addition to all other remedies available to such Holder, such
	Holder, upon written notice to the Company, may void its Conversion
	Notice with respect to, and retain or have returned (as the case
	may be) any Preferred Shares that have not been converted pursuant
	to such Holder’s Conversion Notice, provided that the voiding
	of a Conversion Notice shall not affect the Company’s
	obligations to make any payments which have accrued prior to the
	date of such notice pursuant to the terms of this Certificate of
	Designations or otherwise and (y) the Company shall pay in cash to
	such Holder on each day after such third (3
	rd
	) Trading Day that
	the issuance of such shares of Common Stock is not timely effected
	an amount equal to 1.5% of the product of (A) the aggregate number
	of shares of Common Stock not issued to such Holder on a timely
	basis and to which the Holder is entitled and (B) the Closing Sale
	Price of the Common Stock on the Trading Day immediately preceding
	the last possible date on which the Company could have issued such
	shares of Common Stock to the Holder without violating Section
	4(c). In addition to the foregoing, if within three (3) Trading
	Days after the Company’s receipt of a Conversion Notice
	(whether via facsimile or otherwise), the Company shall fail to
	issue and deliver a certificate to such Holder and register such
	shares of Common Stock on the Company’s share register or
	credit such Holder’s or its designee’s balance account
	with DTC for the number of shares of Common Stock to which such
	Holder is entitled upon such Holder’s conversion hereunder
	(as the case may be), and if on or after such third (3
	rd
	) Trading Day such
	Holder (or any other Person in respect, or on behalf, of such
	Holder) purchases (in an open market transaction or otherwise)
	shares of Common Stock to deliver in satisfaction of a sale by such
	Holder of all or any portion of the number of shares of Common
	Stock, or a sale of a number of shares of Common Stock equal to all
	or any portion of the number of shares of Common Stock, issuable
	upon such conversion that such Holder so anticipated receiving from
	the Company, then, in addition to all other remedies available to
	such Holder, the Company shall, within three (3) Business Days
	after such Holder’s request and in such Holder’s
	discretion, either (i) pay cash to such Holder in an amount equal
	to such Holder’s total purchase price (including brokerage
	commissions and other out-of-pocket expenses, if any) for the
	shares of Common Stock so purchased (including, without limitation,
	by any other Person in respect, or on behalf, of such Holder) (the
	“
	Buy-In Price
	”),
	at which point the Company’s obligation to so issue and
	deliver such certificate or credit such Holder’s balance
	account with DTC for the number of shares of Common Stock to which
	such Holder is entitled upon such Holder’s conversion
	hereunder (as the case may be) (and to issue such shares of Common
	Stock) shall terminate, or (ii) promptly honor its obligation to so
	issue and deliver to such Holder a certificate or certificates
	representing such shares of Common Stock or credit such
	Holder’s balance account with DTC for the number of shares of
	Common Stock to which such Holder is entitled upon such
	Holder’s conversion hereunder (as the case may be) and pay
	cash to such Holder in an amount equal to the excess (if any) of
	the Buy-In Price over the product of (A) such number of shares of
	Common Stock multiplied by (B) the lowest Closing Sale Price of the
	Common Stock on any Trading Day during the period commencing on the
	date of the applicable Conversion Notice and ending on the date of
	such issuance and payment under this clause (ii).
	 
	 
	 
	(v)
	 
	Pro Rata Conversion; Disputes
	.
	In the event the Company receives a Conversion Notice from more
	than one Holder for the same Conversion Date and the Company can
	convert some, but not all, of such Preferred Shares submitted for
	conversion, the Company shall convert from each Holder electing to
	have Preferred Shares converted on such date a pro rata amount of
	such Holder’s Preferred Shares submitted for conversion on
	such date based on the number of Preferred Shares submitted for
	conversion on such date by such Holder relative to the aggregate
	number of Preferred Shares submitted for conversion on such date.
	In the event of a dispute as to the number of shares of Common
	Stock issuable to a Holder in connection with a conversion of
	Preferred Shares, the Company shall issue to such Holder the number
	of shares of Common Stock not in dispute and resolve such dispute
	in accordance with Section 22.
	 
	(vi)
	 
	Book-Entry
	. Notwithstanding
	anything to the contrary set forth in this Section 4, upon
	conversion of any Preferred Shares in accordance with the terms
	hereof, no Holder thereof shall be required to physically surrender
	the certificate representing the Preferred Shares to the Company
	following conversion thereof unless (A) the full or remaining
	number of Preferred Shares represented by the certificate are being
	converted (in which event such certificate(s) shall be delivered to
	the Company as contemplated by this Section 4(c)(vi)) or (B) such
	Holder has provided the Company with prior written notice (which
	notice may be included in a Conversion Notice) requesting
	reissuance of Preferred Shares upon physical surrender of any
	Preferred Shares. Each Holder and the Company shall maintain
	records showing the number of Preferred Shares so converted by such
	Holder and the dates of such conversions or shall use such other
	method, reasonably satisfactory to such Holder and the Company, so
	as not to require physical surrender of the certificate
	representing the Preferred Shares upon each such conversion. In the
	event of any dispute or discrepancy, such records of such Holder
	establishing the number of Preferred Shares to which the record
	holder is entitled shall be controlling and determinative in the
	absence of manifest error. A Holder and any transferee or assignee,
	by acceptance of a certificate, acknowledge and agree that, by
	reason of the provisions of this paragraph, following conversion of
	any Preferred Shares, the number of Preferred Shares represented by
	such certificate may be less than the number of Preferred Shares
	stated on the face thereof. Each certificate for Preferred Shares
	shall bear the following legend:
 
	 
	ANY
	TRANSFEREE OR ASSIGNEE OF THIS CERTIFICATE SHOULD CAREFULLY REVIEW
	THE TERMS OF THE CORPORATION’S CERTIFICATE OF DESIGNATIONS
	RELATING TO THE SHARES OF SERIES L PREFERRED STOCK REPRESENTED BY
	THIS CERTIFICATE, INCLUDING SECTION 4(c)(vi) THEREOF. THE NUMBER OF
	SHARES OF SERIES L PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE
	MAY BE LESS THAN THE NUMBER OF SHARES OF SERIES L PREFERRED STOCK
	STATED ON THE FACE HEREOF PURSUANT TO SECTION 4(c)(vi) OF THE
	CERTIFICATE OF DESIGNATIONS RELATING TO THE SHARES OF SERIES L
	PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE.
	 
	(d)
	 
	Taxes
	. The Company shall pay
	any and all documentary, stamp, transfer (but only in respect of
	the registered holder thereof), issuance and other similar taxes
	that may be payable with respect to the issuance and delivery of
	shares of Common Stock upon the conversion of Preferred
	Shares.
	 
	 
	 
	(e)
	 
	Limitation on Beneficial
	Ownership
	. Notwithstanding anything to the contrary
	contained in this Certificate of Designations, the Preferred Shares
	held by a Holder shall not be convertible by such Holder, and the
	Company shall not effect any conversion of any Preferred Shares
	held by such Holder, to the extent (but only to the extent) that
	such Holder or any of its affiliates would beneficially own in
	excess of 4.99% (the “
	Maximum
	Percentage
	”) of the Common Stock. To the extent
	the above limitation applies, the determination of whether the
	Preferred Shares held by such Holder shall be convertible
	(vis-à-vis other convertible, exercisable or exchangeable
	securities owned by such Holder or any of its affiliates) and of
	which such securities shall be convertible, exercisable or
	exchangeable (as among all such securities owned by such Holder and
	its affiliates) shall, subject to such Maximum Percentage
	limitation, be determined on the basis of the first submission to
	the Company for conversion, exercise or exchange (as the case may
	be). No prior inability of a Holder to convert Preferred Shares, or
	of the Company to issue shares of Common Stock to such Holder,
	pursuant to this Section 4(e) shall have any effect on the
	applicability of the provisions of this Section 4(e) with
	respect to any subsequent determination of convertibility or
	issuance (as the case may be). For purposes of this Section 4(e),
	beneficial ownership and all determinations and calculations
	(including, without limitation, with respect to calculations of
	percentage ownership) shall be determined in accordance with
	Section 13(d) of the 1934 Act and the rules and regulations
	promulgated thereunder. The provisions of this Section 4(e) shall
	be implemented in a manner otherwise than in strict conformity with
	the terms of this Section 4(e) to correct this Section 4(e) (or any
	portion hereof) which may be defective or inconsistent with the
	intended Maximum Percentage beneficial ownership limitation herein
	contained or to make changes or supplements necessary or desirable
	to properly give effect to such Maximum Percentage limitation. The
	limitations contained in this Section 4(e) shall apply to a
	successor holder of Preferred Shares. The holders of Common Stock
	shall be third party beneficiaries of this Section 4(e) and the
	Company may not waive this Section 4(e). For any reason at any
	time, upon the written or oral request of a Holder, the Company
	shall within two (2) Business Days confirm orally and in writing to
	such Holder the number of shares of Common Stock then outstanding,
	including by virtue of any prior conversion or exercise of
	convertible or exercisable securities into Common Stock, including,
	without limitation, pursuant to this Certificate of Designations.
	By written notice to the Company, any Holder may increase or
	decrease the Maximum Percentage to any other percentage not in
	excess of 9.99% specified in such notice; provided that (i) any
	such increase will not be effective until the 61st day after such
	notice is delivered to the Company, and (ii) any such increase or
	decrease will apply only to such Holder sending such notice and not
	to any other Holder. For purposes hereof, in determining the number
	of outstanding shares of Common Stock, the Holder may rely on the
	number of outstanding shares of Common Stock as reflected in (1)
	the Company’s most recent Annual Report on Form 10-K,
	Quarterly Report on Form 10-Q, Current Report on Form 8-K or other
	public filing with the Securities and Exchange Commission, as the
	case may be, (2) a more recent public announcement by the Company,
	or (3) any other notice by the Company setting forth the number of
	shares of Common Stock outstanding. For any reason at any time,
	upon the written or oral request of a holder of Preferred Shares,
	the Company shall within three (3) Business Days confirm orally and
	in writing to such holder the number of shares of Common Stock then
	outstanding. In any case, the number of outstanding shares of
	Common Stock shall be determined after giving effect to the
	conversion or exercise of securities of the Company, including the
	Preferred Shares, by the Holder and its Affiliates since the date
	as of which such number of outstanding shares of Common Stock was
	reported, that in any event are convertible or exercisable, as the
	case may be, into shares of the Company’s Common Stock within
	60 days’ of such calculation and that are not subject to a
	limitation on conversion or exercise analogous to the limitation
	contained herein. The provisions of this paragraph shall be
	construed and implemented in a manner in accordance with Section
	13(d) of the 1934 Act and the rules and regulations promulgated
	thereunder.
	 
	 
	 
	5.
	 
	Rights Upon Issuance of Purchase
	Rights and Other Corporate Events
	.
	 
	(a)
	 
	Purchase Rights
	. In addition to
	any adjustments pursuant to Section 7 below, if at any time the
	Company grants, issues or sells any Options, Convertible Securities
	or rights to purchase stock, warrants, securities or other property
	pro rata to all of the record holders of any class of Common Stock
	(the “
	Purchase
	Rights
	”), then each Holder will be entitled to
	acquire, upon the terms applicable to such Purchase Rights, the
	aggregate Purchase Rights which such Holder could have acquired if
	such Holder had held the number of shares of Common Stock
	acquirable upon complete conversion of all the Preferred Shares
	(without taking into account any limitations or restrictions on the
	convertibility of the Preferred Shares) held by such Holder
	immediately before the date on which a record is taken for the
	grant, issuance or sale of such Purchase Rights, or, if no such
	record is taken, the date as of which the record holders of Common
	Stock are to be determined for the grant, issue or sale of such
	Purchase Rights (provided, however, to the extent that such
	Holder’s right to participate in any such Purchase Right
	would result in such Holder exceeding the Maximum Percentage, then
	such Holder shall not be entitled to participate in such Purchase
	Right to such extent (or beneficial ownership of such shares of
	Common Stock as a result of such Purchase Right to such extent) and
	such Purchase Right to such extent shall be held in abeyance for
	such Holder until such time, if ever, as its right thereto would
	not result in such Holder exceeding the Maximum
	Percentage).
 
	 
	(b)
	 
	Other Corporate Events
	. In
	addition to and not in substitution for any other rights hereunder,
	prior to the consummation of any Fundamental Transaction pursuant
	to which holders of shares of Common Stock are entitled to receive
	securities or other assets with respect to or in exchange for
	shares of Common Stock (a “
	Corporate Event
	”), the Company
	shall make appropriate provision to insure that each Holder will
	thereafter have the right to receive upon a conversion of all the
	Preferred Shares held by such Holder (i) in addition to the shares
	of Common Stock receivable upon such conversion, such securities or
	other assets to which such Holder would have been entitled with
	respect to such shares of Common Stock had such shares of Common
	Stock been held by such Holder upon the consummation of such
	Corporate Event (without taking into account any limitations or
	restrictions on the convertibility of the Preferred Shares
	contained in this Certificate of Designations) or (ii) in lieu of
	the shares of Common Stock otherwise receivable upon such
	conversion, such securities or other assets received by the holders
	of shares of Common Stock in connection with the consummation of
	such Corporate Event in such amounts as such Holder would have been
	entitled to receive had the Preferred Shares held by such Holder
	initially been issued with conversion rights for the form of such
	consideration (as opposed to shares of Common Stock) at a
	conversion rate for such consideration commensurate with the
	Conversion Rate. The provisions of this Section 5(b) shall apply
	similarly and equally to successive Corporate Events and shall be
	applied without regard to any limitations on the conversion of the
	Preferred Shares contained in this Certificate of
	Designations.
 
	 
	6.
	 
	Rights Upon Fundamental
	Transactions
	. Upon the occurrence of any Fundamental
	Transaction, the Successor Entity shall succeed to, and be
	substituted for (so that from and after the date of such
	Fundamental Transaction, the provisions of this Certificate of
	Designations referring to the “Company” shall refer
	instead to the Successor Entity), and may exercise every right and
	power of the Company and shall assume all of the obligations of the
	Company under this Certificate of Designations with the same effect
	as if such Successor Entity had been named as the Company herein
	and therein. In addition to the foregoing, upon consummation of a
	Fundamental Transaction, the Successor Entity shall deliver to each
	Holder confirmation that there shall be issued upon conversion of
	the Preferred Shares at any time after the consummation of such
	Fundamental Transaction, in lieu of the shares of Common Stock (or
	other securities, cash, assets or other property (except such items
	still issuable under Sections 5 and 11, which shall continue to be
	receivable thereafter)) issuable upon the conversion of the
	Preferred Shares prior to such Fundamental Transaction, such shares
	of the Successor Entity (including its Parent Entity) or other
	consideration which each Holder would have been entitled to receive
	upon the happening of such Fundamental Transaction had all the
	Preferred Shares held by each Holder been converted immediately
	prior to such Fundamental Transaction (without regard to any
	limitations on the conversion of the Preferred Shares contained in
	this Certificate of Designations), as adjusted in accordance with
	the provisions of this Certificate of Designations. The provisions
	of this Section 6 shall apply similarly and equally to successive
	Fundamental Transactions and shall be applied without regard to any
	limitations on the conversion of the Preferred Shares.
 
	 
	 
	 
	7.
	 
	Rights Upon
	Issuance of Other Securities.
	 
	(a)
	 
	Reserved.
	 
	(b)
	 
	Adjustment of
	Conversion Price upon Subdivision or Combination of Common Stock.
	Without limiting any provision of Sections 5 and 11, if the Company
	at any time on or after the Initial Issuance Date subdivides (by
	any stock split, stock dividend, recapitalization or otherwise) one
	or more classes of its outstanding shares of Common Stock into a
	greater number of shares, the Conversion Price in effect
	immediately prior to such subdivision will be proportionately
	reduced. Without limiting any provision of Sections 5 and 11, if
	the Company at any time on or after the Initial Issuance Date
	combines (by combination, reverse stock split or otherwise) one or
	more classes of its outstanding shares of Common Stock into a
	smaller number of shares, the Conversion Price in effect
	immediately prior to such combination will be proportionately
	increased. Any adjustment pursuant to this Section 7(b) shall
	become effective immediately after the effective date of such
	subdivision or combination. If any event requiring an adjustment
	under this Section 7(b) occurs during the period that a Conversion
	Price is calculated hereunder, then the calculation of such
	Conversion Price shall be adjusted appropriately to reflect such
	event.
 
	 
	(c)
	 
	Calculations. All
	calculations under this Section 7 shall be made by rounding to the
	nearest one-hundred thousandth of a cent or the nearest
	1/100
	th
	of
	a share, as applicable. The number of shares of Common Stock
	outstanding at any given time shall not include shares owned or
	held by or for the account of the Company, and the disposition of
	any such shares shall be considered an issue or sale of Common
	Stock.
	 
	 
	(a)
	 
	Reservation
	. The Company shall
	initially reserve out of its authorized and unissued Common Stock a
	number of shares of Common Stock equal to 100% of the Conversion
	Rate with respect to the Base Amount of each Preferred Share as of
	the Initial Issuance Date (without taking into account any
	limitations on the conversion of such Preferred Shares set forth in
	herein) issuable pursuant to the terms of this Certificate of
	Designations from the Initial Issuance Date through the second
	anniversary of the Initial Issuance Date assuming (without taking
	into account any limitations on the issuance of securities set
	forth herein). So long as any of the Preferred Shares are
	outstanding, the Company shall take all action necessary to reserve
	and keep available out of its authorized and unissued shares of
	Common Stock, solely for the purpose of effecting the conversion of
	the Preferred Shares, as of any given date, 100% of the number of
	shares of Common Stock as shall from time to time be necessary to
	effect the conversion of all of the Preferred Shares issued as of
	the Initial Issuance Date, without taking into account any
	limitations on the issuance of securities set forth herein),
	provided that at no time shall the number of shares of Common Stock
	so available be less than the number of shares required to be
	reserved by the previous sentence (without regard to any
	limitations on conversions contained in this Certificate of
	Designations) (the “
	Required
	Amount
	”). The initial number of shares of Common Stock
	reserved for conversions of the Preferred Shares and each increase
	in the number of shares so reserved shall be allocated pro rata
	among the Holders based on the number of Preferred Shares held by
	each Holder on the Initial Issuance Date or increase in the number
	of reserved shares (as the case may be) (the “
	Authorized Share Allocation
	”). In
	the event a Holder shall sell or otherwise transfer any of such
	Holder’s Preferred Shares, each transferee shall be allocated
	a pro rata portion of such Holder’s Authorized Share
	Allocation. Any shares of Common Stock reserved and allocated to
	any Person which ceases to hold any Preferred Shares shall be
	allocated to the remaining Holders of Preferred Shares, pro rata
	based on the number of Preferred Shares then held by such
	Holders.
 
	 
	 
	 
	(b)
	 
	Insufficient Authorized Shares
	.
	If, notwithstanding Section 8(a) and not in limitation thereof, at
	any time while any of the Preferred Shares remain outstanding the
	Company does not have a sufficient number of authorized and
	unissued shares of Common Stock to satisfy its obligation to have
	available for issuance upon conversion of the Preferred Shares at
	least a number of shares of Common Stock equal to the Required
	Amount (an “
	Authorized Share
	Failure
	”), then the Company shall promptly take all
	action necessary to increase the Company’s authorized shares
	of Common Stock to an amount sufficient to allow the Company to
	reserve and have available the Required Amount for all of the
	Preferred Shares then outstanding. Without limiting the generality
	of the foregoing sentence, as soon as practicable after the date of
	the occurrence of an Authorized Share Failure, but in no event
	later than ninety (90) days after the occurrence of such Authorized
	Share Failure, the Company shall hold a meeting of its stockholders
	or conduct a consent solicitation for the approval of an increase
	in the number of authorized shares of Common Stock. In connection
	with such meeting, the Company shall provide each stockholder with
	a proxy statement and shall use its commercially reasonable efforts
	to solicit its stockholders’ approval of such increase in
	authorized shares of Common Stock and to cause its Board to
	recommend to the stockholders that they approve such proposal. In
	the event that the Company is prohibited from issuing shares of
	Common Stock upon a conversion of any Preferred Share due to the
	failure by the Company to have sufficient shares of Common Stock
	available out of the authorized but unissued shares of Common Stock
	(such unavailable number of shares of Common Stock, the
	“
	Authorization Failure
	Shares
	”), in lieu of delivering such Authorization
	Failure Shares to such Holder of such Preferred Shares, the Company
	shall pay cash in exchange for the cancellation of such Preferred
	Shares convertible into such Authorized Failure Shares at a price
	equal to the sum of (i) the product of (x) such number of
	Authorization Failure Shares and (y) the Closing Sale Price on the
	Trading Day immediately preceding the date such Holder delivers the
	applicable Conversion Notice with respect to such Authorization
	Failure Shares to the Company and (ii) to the extent such Holder
	purchases (in an open market transaction or otherwise) shares of
	Common Stock to deliver in satisfaction of a sale by such Holder of
	Authorization Failure Shares, any brokerage commissions and other
	out-of-pocket expenses, if any, of such Holder incurred in
	connection therewith.
	 
	9.
	 
	Voting Rights
	. Except as
	otherwise expressly required by law, each holder of Preferred
	Shares shall be entitled to vote on all matters submitted to
	shareholders of the Company and shall be entitled to the number of
	votes for each Preferred Share owned at the record date for the
	determination of shareholders entitled to vote on such matter or,
	if no such record date is established, at the date such vote is
	taken or any written consent of shareholders is solicited, equal to
	the number of shares of Common Stock such Preferred Shares are
	convertible into (voting as a class with Common Stock) substituting
	the consolidated Closing Bid Price on October 13, 2017 for the
	Conversion Rate in Section 4(b) hereof, but not in excess of the
	conversion limitations set forth in Section 4(e) herein. Except as
	otherwise required by law, the holders of Preferred Shares shall
	vote together with the holders of Common Stock on all matters and
	shall not vote as a separate class.
	 
	10.
	 
	Liquidation, Dissolution,
	Winding-Up
	. In the event of a Liquidation Event, the Holders
	shall be entitled to receive in cash out of the assets of the
	Company, whether from capital or from earnings available for
	distribution to its shareholders (the “
	Liquidation Funds
	”), before any
	amount shall be paid to the holders of any of shares of Junior
	Stock, an amount per Preferred Share equal to the greater of (a)
	100% of the Base Amount thereof on the date of such payment, and
	(b) the amount per share such Holder would receive if such Holder
	converted such Preferred Shares into Common Stock immediately prior
	to the date of such payment;
	provided
	,
	however
	, that, if the
	Liquidation Funds are insufficient to pay the full amount due to
	the Holders and holders of shares of Parity Stock (stock ranking
	equal to the Preferred Shares), then each Holder and each holder of
	Parity Stock shall receive a percentage of the Liquidation Funds
	equal to the full amount of Liquidation Funds payable to such
	Holder and such holder of Parity Stock as a liquidation preference,
	in accordance with their respective certificate of designation (or
	equivalent), as a percentage of the full amount of Liquidation
	Funds payable to all holders of Preferred Shares and all holders of
	shares of Parity Stock. To the extent necessary, the Company shall
	cause such actions to be taken by each of its Subsidiaries so as to
	enable, to the maximum extent permitted by law, the proceeds of a
	Liquidation Event to be distributed to the Holders in accordance
	with this Section 10. All the preferential amounts to be paid to
	the Holders under this Section 10 shall be paid or set apart for
	payment before the payment or setting apart for payment of any
	amount for, or the distribution of any Liquidation Funds of the
	Company to the holders of shares of Junior Stock in connection with
	a Liquidation Event as to which this Section 10
	applies.
	 
	 
	 
	11.
	 
	Participation
	. In addition to
	any adjustments pursuant to Section 7(b), the Holders shall, as
	holders of Preferred Shares, be entitled to receive such dividends
	paid and distributions made to the holders of shares of Common
	Stock to the same extent as if such Holders had converted each
	Preferred Share held by each of them into shares of Common Stock
	(without regard to any limitations on conversion herein or
	elsewhere) and had held such shares of Common Stock on the record
	date for such dividends and distributions. Payments under the
	preceding sentence shall be made concurrently with the dividend or
	distribution to the holders of shares of Common Stock (provided,
	however, to the extent that a Holder’s right to participate
	in any such dividend or distribution would result in such Holder
	exceeding the Maximum Percentage, then such Holder shall not be
	entitled to participate in such dividend or distribution to such
	extent (or the beneficial ownership of any such shares of Common
	Stock as a result of such dividend or distribution to such extent)
	and such dividend or distribution to such extent shall be held in
	abeyance for the benefit of such Holder until such time, if ever,
	as its right thereto would not result in such Holder exceeding the
	Maximum Percentage).
	 
	12.
	 
	Vote to Change the Terms of or Issue
	Preferred Shares
	. In addition to any other rights provided
	by law, except where the vote or written consent of the holders of
	a greater number of shares is required by law or by another
	provision of the Certificate of Incorporation, without first
	obtaining the affirmative vote at a meeting duly called for such
	purpose or the written consent without a meeting of the Holders of
	Preferred Shares representing a majority of Preferred Shares
	outstanding on such date (the “
	Required Holders
	”), voting
	together as a single class, the Company shall not: (a) amend or
	repeal any provision of, or add any provision to, its Certificate
	of Incorporation or bylaws, or file any certificate of designations
	or articles of amendment of any series of shares of preferred
	stock, if such action would adversely alter or change in any
	respect the preferences, rights, privileges or powers, or
	restrictions provided for the benefit, of the Preferred Shares,
	regardless of whether any such action shall be by means of
	amendment to the Certificate of Incorporation or by merger,
	consolidation or otherwise; (b) increase or decrease (other than by
	conversion) the authorized number of Preferred Shares; (c) issue
	any Preferred Shares after the Initial Issuance Date; or (d)
	without limiting any provision of Section 16, whether or not
	prohibited by the terms of the Preferred Shares, circumvent a right
	of the Preferred Shares.
	 
	13.
	 
	Intentionally
	Omitted
	.
	 
	14.
	 
	Lost or Stolen Certificates
	.
	Upon receipt by the Company of evidence reasonably satisfactory to
	the Company of the loss, theft, destruction or mutilation of any
	certificates representing Preferred Shares (as to which a written
	certification and the indemnification contemplated below shall
	suffice as such evidence), and, in the case of loss, theft or
	destruction, of an indemnification undertaking by the applicable
	Holder to the Company in customary and reasonable form and, in the
	case of mutilation, upon surrender and cancellation of the
	certificate(s), the Company shall execute and deliver new
	certificate(s) of like tenor and date.
	 
	15.
	 
	Remedies, Characterizations, Other
	Obligations, Breaches and Injunctive Relief.
	The remedies
	provided in this Certificate of Designations shall be cumulative
	and in addition to all other remedies available under this
	Certificate of Designations, at law or in equity (including a
	decree of specific performance and/or other injunctive relief), and
	no remedy contained herein shall be deemed a waiver of compliance
	with the provisions giving rise to such remedy. Nothing herein
	shall limit any Holder’s right to pursue actual and
	consequential damages for any failure by the Company to comply with
	the terms of this Certificate of Designations. The Company
	covenants to each Holder that there shall be no characterization
	concerning this instrument other than as expressly provided herein.
	Amounts set forth or provided for herein with respect to payments,
	conversion and the like (and the computation thereof) shall be the
	amounts to be received by a Holder and shall not, except as
	expressly provided herein, be subject to any other obligation of
	the Company (or the performance thereof). The Company acknowledges
	that a breach by it of its obligations hereunder will cause
	irreparable harm to the Holders and that the remedy at law for any
	such breach may be inadequate. The Company therefore agrees that,
	in the event of any such breach or threatened breach, each Holder
	shall be entitled, in addition to all other available remedies, to
	an injunction restraining any such breach or any such threatened
	breach, without the necessity of showing economic loss and without
	any bond or other security being required. The Company shall
	provide all information and documentation to a Holder that is
	requested by such Holder to enable such Holder to confirm the
	Company’s compliance with the terms and conditions of this
	Certificate of Designations.
	 
	 
	 
	16.
	 
	Noncircumvention
	. The Company
	hereby covenants and agrees that the Company will not, by amendment
	of its Certificate of Incorporation, bylaws or through any
	reorganization, transfer of assets, consolidation, merger, scheme
	of arrangement, dissolution, issue or sale of securities, or any
	other voluntary action, avoid or seek to avoid the observance or
	performance of any of the terms of this Certificate of
	Designations, and will at all times in good faith carry out all the
	provisions of this Certificate of Designations and take all action
	as may be required to protect the rights of the Holders. Without
	limiting the generality of the foregoing or any other provision of
	this Certificate of Designations, the Company (i) shall not
	increase the par value of any shares of Common Stock receivable
	upon the conversion of any Preferred Shares above the Conversion
	Price then in effect, (ii) shall take all such actions as may
	be necessary or appropriate in order that the Company may validly
	and legally issue fully paid and non-assessable shares of Common
	Stock upon the conversion of Preferred Shares and (iii) shall, so
	long as any Preferred Shares are outstanding, take all action
	necessary to reserve and keep available out of its authorized and
	unissued shares of Common Stock, solely for the purpose of
	effecting the conversion of the Preferred Shares, the maximum
	number of shares of Common Stock as shall from time to time be
	necessary to effect the conversion of the Preferred Shares then
	outstanding (without regard to any limitations on conversion
	contained herein).
	 
	17.
	 
	Failure
	or Indulgence Not Waiver
	. No failure or delay on the part of
	a Holder in the exercise of any power, right or privilege hereunder
	shall operate as a waiver thereof, nor shall any single or partial
	exercise of any such power, right or privilege preclude other or
	further exercise thereof or of any other right, power or privilege.
	No waiver shall be effective unless it is in writing and signed by
	an authorized representative of the waiving party. This Certificate
	of Designations shall be deemed to be jointly drafted by the
	Company and all Holders and shall not be construed against any
	Person as the drafter hereof.
	 
	18.
	 
	Notices
	. The Company shall
	provide each Holder of Preferred Shares with prompt written notice
	of all actions taken pursuant to the terms of this Certificate of
	Designations, including in reasonable detail a description of such
	action and the reason therefor. Whenever notice is required to be
	given under this Certificate of Designations, unless otherwise
	provided herein. Without limiting the generality of the foregoing,
	the Company shall give written notice to each Holder (i) promptly
	following any adjustment of the Conversion Price, setting forth in
	reasonable detail, and certifying, the calculation of such
	adjustment and (ii) at least fifteen (15) days prior to the date on
	which the Company closes its books or takes a record (A) with
	respect to any dividend or distribution upon the Common Stock, (B)
	with respect to any grant, issuances, or sales of any Options,
	Convertible Securities or rights to purchase stock, warrants,
	securities or other property to all holders of shares of Common
	Stock as a class or (C) for determining rights to vote with respect
	to any Fundamental Transaction, dissolution or liquidation,
	provided, in each case, that such information shall be made known
	to the public prior to, or simultaneously with, such notice being
	provided to any Holder.
	 
	19.
	 
	Transfer of Preferred Shares
	.
	The Holder may transfer some or all of its Preferred Shares without
	the consent of the Company.
	 
	20.
	 
	Preferred Shares Register
	. The
	Company shall maintain at its principal executive offices (or such
	other office or agency of the Company as it may designate by notice
	to the Holders), a register for the Preferred Shares, in which the
	Company shall record the name, address and facsimile number of the
	Persons in whose name the Preferred Shares have been issued, as
	well as the name and address of each transferee. The Company may
	treat the Person in whose name any Preferred Shares is registered
	on the register as the owner and holder thereof for all purposes,
	notwithstanding any notice to the contrary, but in all events
	recognizing any properly made transfers.
	 
	 
	 
	21.
	 
	Stockholder Matters;
	Amendment
	.
	 
	(a)
	 
	Stockholder
	Matters. Any stockholder action, approval or consent required,
	desired or otherwise sought by the Company pursuant to the DGCL,
	the Certificate of Incorporation, this Certificate of Designations
	or otherwise with respect to the issuance of Preferred Shares may
	be effected by written consent of the Company’s stockholders
	or at a duly called meeting of the Company’s stockholders,
	all in accordance with the applicable rules and regulations of the
	DGCL. This provision is intended to comply with the applicable
	sections of the DGCL permitting stockholder action, approval and
	consent affected by written consent in lieu of a
	meeting.
	 
	(b)
	 
	Amendment. This
	Certificate of Designations or any provision hereof may be amended
	by obtaining the affirmative vote at a meeting duly called for such
	purpose, or written consent without a meeting in accordance with
	the DGCL, of the Required Holders, voting separate as a single
	class, and with such other stockholder approval, if any, as may
	then be required pursuant to the DGCL and the Certificate of
	Incorporation.
	 
	 
	(a)
	 
	Disputes Over Closing Bid Price,
	Closing Sale Price, Conversion Price or Fair Market
	Value.
 
	 
	(i)
	 
	In the case of a
	dispute relating to a Closing Bid Price, a Closing Sale Price, a
	Conversion Price or fair market value (as the case may be)
	(including, without limitation, a dispute relating to the
	determination of any of the foregoing), the Company or such
	applicable Holder (as the case may be) shall submit the dispute via
	facsimile (I) within two (2) Business Days after delivery of the
	applicable notice giving rise to such dispute to the Company or
	such Holder (as the case may be) or (II) if no notice gave rise to
	such dispute, at any time after such Holder learned of the
	circumstances giving rise to such dispute. If such Holder and the
	Company are unable to resolve such dispute relating to such Closing
	Bid Price, such Closing Sale Price, such Conversion Price, or such
	fair market value (as the case may be) by 5:00 p.m. (New York time)
	on the third (3
	rd
	) Business Day
	following such delivery by the Company or such Holder (as the case
	may be) of such dispute to the Company or such Holder (as the case
	may be), then such Holder shall select an independent, reputable
	investment bank to resolve such dispute.
	 
	(ii)
	 
	Such
	Holder and the Company shall each deliver to such investment bank
	(x) a copy of the initial dispute submission so delivered in
	accordance with the first sentence of this Section 22(a) and (y)
	written documentation supporting its position with respect to such
	dispute, in each case, no later than 5:00 p.m. (New York time) by
	the fifth (5
	th
	) Business Day
	immediately following the date on which such Holder selected such
	investment bank (the “
	Dispute
	Submission Deadline
	”) (the documents referred to in
	the immediately preceding clauses (x) and (y) are collectively
	referred to herein as the “
	Required Dispute Documentation
	”)
	(it being understood and agreed that if either such Holder or the
	Company fails to so deliver all of the Required Dispute
	Documentation by the Dispute Submission Deadline, then the party
	who fails to so submit all of the Required Dispute Documentation
	shall no longer be entitled to (and hereby waives its right to)
	deliver or submit any written documentation or other support to
	such investment bank with respect to such dispute and such
	investment bank shall resolve such dispute based solely on the
	Required Dispute Documentation that was delivered to such
	investment bank prior to the Dispute Submission Deadline). Unless
	otherwise agreed to in writing by both the Company and such Holder
	or otherwise requested by such investment bank, neither the Company
	nor such Holder shall be entitled to deliver or submit any written
	documentation or other support to such investment bank in
	connection with such dispute (other than the Required Dispute
	Documentation).
	 
	 
	 
	(iii)
	 
	The
	Company and such Holder shall cause such investment bank to
	determine the resolution of such dispute and notify the Company and
	such Holder of such resolution no later than ten (10) Business Days
	immediately following the Dispute Submission Deadline. The fees and
	expenses of such investment bank shall be borne solely by the
	Company, and such investment bank’s resolution of such
	dispute shall be final and binding upon all parties absent manifest
	error.
	 
	(b)
	 
	Disputes Over Arithmetic Calculation
	of the Conversion Rate.
 
	 
	(i)
	 
	In the case of a
	dispute as to the arithmetic calculation of a Conversion Rate, the
	Company or such Holder (as the case may be) shall submit the
	disputed arithmetic calculation via facsimile (i) within two (2)
	Business Days after delivery of the applicable notice giving rise
	to such dispute to the Company or such Holder (as the case may be)
	or (ii) if no notice gave rise to such dispute, at any time after
	such Holder learned of the circumstances giving rise to such
	dispute. If such Holder and the Company are unable to resolve such
	disputed arithmetic calculation of such Conversion Rate by 5:00
	p.m. (New York time) on the third (3
	rd
	) Business Day
	following such delivery by the Company or such Holder (as the case
	may be) of such disputed arithmetic calculation, then such Holder
	shall select an independent, reputable accountant or accounting
	firm to perform such disputed arithmetic calculation.
	 
	(ii)
	 
	Such
	Holder and the Company shall each deliver to such accountant or
	accounting firm (as the case may be) (x) a copy of the initial
	dispute submission so delivered in accordance with the first
	sentence of this Section 22(a) and (y) written documentation
	supporting its position with respect to such disputed arithmetic
	calculation, in each case, no later than 5:00 p.m. (New York time)
	by the fifth (5
	th
	) Business Day
	immediately following the date on which such Holder selected such
	accountant or accounting firm (as the case may be) (the
	“
	Submission
	Deadline
	”) (the documents referred to in the
	immediately preceding clauses (x) and (y) are collectively referred
	to herein as the “
	Required
	Documentation
	”) (it being understood and agreed that
	if either such Holder or the Company fails to so deliver all of the
	Required Documentation by the Submission Deadline, then the party
	who fails to so submit all of the Required Documentation shall no
	longer be entitled to (and hereby waives its right to) deliver or
	submit any written documentation or other support to such
	accountant or accounting firm (as the case may be) with respect to
	such disputed arithmetic calculation and such accountant or
	accounting firm (as the case may be) shall perform such disputed
	arithmetic calculation based solely on the Required Documentation
	that was delivered to such accountant or accounting firm (as the
	case may be) prior to the Submission Deadline). Unless otherwise
	agreed to in writing by both the Company and such Holder or
	otherwise requested by such accountant or accounting firm (as the
	case may be), neither the Company nor such Holder shall be entitled
	to deliver or submit any written documentation or other support to
	such accountant or accounting firm (as the case may be) in
	connection with such disputed arithmetic calculation of the
	Conversion Rate (other than the Required
	Documentation).
	 
	(iii)
	 
	The
	Company and such Holder shall cause such accountant or accounting
	firm (as the case may be) to perform such disputed arithmetic
	calculation and notify the Company and such Holder of the results
	no later than ten (10) Business Days immediately following the
	Submission Deadline. The fees and expenses of such accountant or
	accounting firm (as the case may be) shall be borne solely by the
	Company, and such accountant’s or accounting firm’s (as
	the case may be) arithmetic calculation shall be final and binding
	upon all parties absent manifest error.
	 
	 
	 
	(c)
	 
	Miscellaneous. The
	Company expressly acknowledges and agrees that (i) this Section 22
	constitutes an agreement to arbitrate between the Company and such
	Holder (and constitutes an arbitration agreement) under §
	7501, et seq. of the New York Civil Practice Law and Rules
	(“
	CPLR
	”) and
	that each party shall be entitled to compel arbitration pursuant to
	CPLR § 7503(a) in order to compel compliance with this Section
	22, (ii) the terms of this Certificate of Designations shall serve
	as the basis for the selected investment bank’s resolution of
	the applicable dispute, such investment bank shall be entitled (and
	is hereby expressly authorized) to make all findings,
	determinations and the like that such investment bank determines
	are required to be made by such investment bank in connection with
	its resolution of such dispute and in resolving such dispute such
	investment bank shall apply such findings, determinations and the
	like to the terms of this Certificate of Designations, (iii) the
	terms of this Certificate of Designations shall serve as the basis
	for the selected accountant’s or accounting firm’s
	performance of the applicable arithmetic calculation, (iv) for
	clarification purposes and without implication that the contrary
	would otherwise be true, disputes relating to matters described in
	Section 22(a) shall be governed by Section 22(a) and not by Section
	22(b), (v) such Holder (and only such Holder), in its sole
	discretion, shall have the right to submit any dispute described in
	this Section 22 to any state or federal court sitting in The City
	of New York, Borough of Manhattan in lieu of utilizing the
	procedures set forth in this Section 22 and (vi) nothing in this
	Section 22 shall limit such Holder from obtaining any injunctive
	relief or other equitable remedies (including, without limitation,
	with respect to any matters described in Section 22(a) or Section
	22(b)).
	 
	23.
	 
	Certain Defined Terms
	. For
	purposes of this Certificate of Designations, the following terms
	shall have the following meanings:
 
	 
	(a)
	 
	“
	1934
	Act
	”
	 
	means
	 
	the Securities Exchange Act of
	1934, as amended.
	 
	(b)
	 
	“
	Base Amount
	” means, with respect
	to each Preferred Share, as of the applicable date of
	determination, the sum of (1) the Stated Value thereof, plus (2)
	the Unpaid Dividend Amount thereon as of such date of
	determination.
	 
	(c)
	 
	“
	Bloomberg
	” means Bloomberg,
	L.P.
	 
	(d)
	 
	“
	Business Day
	” means any day other
	than Saturday, Sunday or other day on which commercial banks in The
	City of New York are authorized or required by law to remain
	closed.
	 
	(e)
	 
	“
	Closing Bid Price
	” and
	“
	Closing Sale
	Price
	” means, for any security as of any date, the
	last closing bid price and last closing trade price, respectively,
	for such security on the Principal Market, as reported by
	Bloomberg, or, if the Principal Market begins to operate on an
	extended hours basis and does not designate the closing bid price
	or the closing trade price (as the case may be) then the last bid
	price or last trade price, respectively, of such security prior to
	4:00:00 p.m., New York time, as reported by Bloomberg, or, if the
	Principal Market is not the principal securities exchange or
	trading market for such security, the last closing bid price or
	last trade price, respectively, of such security on the principal
	securities exchange or trading market where such security is listed
	or traded as reported by Bloomberg, or if the foregoing do not
	apply, the last closing bid price or last trade price,
	respectively, of such security in the over-the-counter market on
	the electronic bulletin board for such security as reported by
	Bloomberg, or, if no closing bid price or last trade price,
	respectively, is reported for such security by Bloomberg, the
	average of the bid prices, or the ask prices, respectively, of any
	market makers for such security as reported in the “pink
	sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC).
	If the Closing Bid Price or the Closing Sale Price cannot be
	calculated for a security on a particular date on any of the
	foregoing bases, the Closing Bid Price or the Closing Sale Price
	(as the case may be) of such security on such date shall be the
	fair market value as mutually determined by the Company and the
	applicable Holder. If the Company and such Holder are unable to
	agree upon the fair market value of such security, then such
	dispute shall be resolved in accordance with the procedures in
	Section 22. All such determinations shall be appropriately adjusted
	for any stock dividend, stock split, stock combination or other
	similar transaction during such period.
	 
	 
	 
	(f)
	 
	“
	Common Stock
	” means (i) the
	Company’s shares of common stock, $0.01 par value per share,
	and (ii) any capital stock into which such common stock shall have
	been changed or any share capital resulting from a reclassification
	of such common stock.
	 
	(g)
	 
	“
	Conversion Price
	” means, with
	respect to each Preferred Share, as of any Conversion Date or other
	applicable date of determination,
	$0.60,
	subject to adjustment as provided
	herein.
	 
	(h)
	 
	 “
	Convertible
	Securities
	” means any stock or other security (other
	than Options) that is at any time and under any circumstances,
	directly or indirectly, convertible into, exercisable or
	exchangeable for, or which otherwise entitles the holder thereof to
	acquire, any shares of Common Stock.
	 
	(i)
	 
	“
	Eligible Market
	” means The New
	York Stock Exchange, the NYSE MKT, The Nasdaq Global Select Market,
	The Nasdaq Global Market, The Nasdaq Capital Market, the
	Over-the-Counter Bulletin Board, the OTCQB Marketplace or the OTCQX
	(or any successor thereto).
	 
	(j)
	 
	“
	Fundamental Transaction
	” means
	that (i) the Company or any of its Subsidiaries shall, directly or
	indirectly, in one or more related transactions, (1) consolidate or
	merge with or into (whether or not the Company or any of its
	Subsidiaries is the surviving corporation) any other Person unless
	immediately following the closing of such transaction or series of
	related transactions the Persons holding more than 50% of the
	Voting Stock of the Company prior to such closing continue to hold
	more than 50% of the Voting Stock of the Company following such
	closing, or (2) sell, lease, license, assign, transfer, convey or
	otherwise dispose of all or substantially all of its respective
	properties or assets to any other Person, or (3) assist any other
	Person in making a purchase, tender or exchange offer that is
	accepted by the holders of more than 50% of the outstanding shares
	of Voting Stock of the Company (not including any shares of Voting
	Stock of the Company held by the Person or Persons making or party
	to, or associated or affiliated with the Persons making or party
	to, such purchase, tender or exchange offer), or (4) consummate a
	stock or share purchase agreement or other business combination
	(including, without limitation, a reorganization, recapitalization,
	spin-off or scheme of arrangement) with any other Person whereby
	such other Person acquires more than 50% of the outstanding shares
	of Voting Stock of the Company (not including any shares of Voting
	Stock of the Company held by the other Person or other Persons
	making or party to, or associated or affiliated with the other
	Persons making or party to, such stock or share purchase agreement
	or other business combination) excluding any equity financing
	transaction in which shares of Voting Stock are issued, or (5)
	reorganize, recapitalize or reclassify the Common Stock, or (ii)
	any “person” or “group” (as these terms are
	used for purposes of Sections 13(d) and 14(d) of the 1934 Act and
	the rules and regulations promulgated thereunder) is or shall
	become the “beneficial owner” (as defined in Rule 13d-3
	under the 1934 Act), directly or indirectly, of 50% of the
	aggregate ordinary voting power represented by issued and
	outstanding Voting Stock of the Company.
	 
	(k)
	 
	“
	Liquidation Event
	” means the
	liquidation, dissolution or winding up of the affairs of the
	Company, whether voluntary or involuntary. Notwithstanding the
	foregoing, a consolidation or merger of the Company with or into
	any other corporation or corporations, or a sale of all or
	substantially all of the assets of the Company, or the effectuation
	by the Company of a transaction or series of transactions in which
	more than 50% of the voting shares of the Company is disposed of or
	conveyed, shall be deemed to be a Liquidation Event.
	 
	(l)
	 
	“
	Options
	” means any rights,
	warrants or options to subscribe for or purchase shares of Common
	Stock or Convertible Securities.
	 
	 
	 
	(m)
	 
	“
	Parent Entity
	” of a Person means
	an entity that, directly or indirectly, controls the applicable
	Person and whose common stock or equivalent equity security is
	quoted or listed on an Eligible Market, or, if there is more than
	one such Person or Parent Entity, the Person or Parent Entity with
	the largest public market capitalization as of the date of
	consummation of the Fundamental Transaction.
	 
	(n)
	 
	 “
	Person
	”
	means an individual, a limited liability company, a partnership, a
	joint venture, a corporation, a trust, an unincorporated
	organization, any other entity or a government or any department or
	agency thereof.
	 
	(o)
	 
	 “
	Principal
	Market
	” means the The NASDAQ Capital
	Market.
	 
	(p)
	 
	Reserved.
	 
	(q)
	 
	 “
	SEC
	”
	means the Securities and Exchange Commission or the successor
	thereto.
	 
	(r)
	 
	“
	Stated Value
	” shall mean $100 per
	share, subject to adjustment for stock splits, stock dividends,
	recapitalizations, reorganizations, reclassifications,
	combinations, subdivisions or other similar events occurring after
	the Initial Issuance Date with respect to the Preferred
	Shares.
	 
	(s)
	 
	“
	Subsidiaries
	” means any Person in
	which the Company, directly or indirectly, (I) owns any of the
	outstanding capital stock or holds any equity or similar interest
	of such Person or (II) controls or operates all or any part of the
	business, operations or administration of such Person.
	 
	(t)
	 
	“
	Successor Entity
	” means the Person
	(or, if so elected by the Required Holders, the Parent Entity)
	formed by, resulting from or surviving any Fundamental Transaction
	or the Person (or, if so elected by the Required Holders, the
	Parent Entity) with which such Fundamental Transaction shall have
	been entered into.
	 
	(u)
	 
	“
	Trading Day
	” means, as applicable,
	(x) with respect to all price determinations relating to the Common
	Stock, any day on which the Common Stock is traded on the Principal
	Market, or, if the Principal Market is not the principal trading
	market for the Common Stock, then on the principal securities
	exchange or securities market on which the Common Stock is then
	traded, provided that “Trading Day” shall not include
	any day on which the Common Stock is scheduled to trade on such
	exchange or market for less than 4.5 hours or any day that the
	Common Stock is suspended from trading during the final hour of
	trading on such exchange or market (or if such exchange or market
	does not designate in advance the closing time of trading on such
	exchange or market, then during the hour ending at 4:00:00 p.m.,
	New York time) unless such day is otherwise designated as a Trading
	Day in writing by the Required Holders or (y) with respect to all
	determinations other than price determinations relating to the
	Common Stock, any day on which The NASDAQ Stock Market (or any
	successor thereto) is open for trading of securities.
	 
	(v)
	 
	“
	Unpaid Dividend Amount
	” means, as
	of the applicable date of determination, with respect to each
	Preferred Share, all declared and unpaid Dividends on such
	Preferred Share.
	 
	(w)
	 
	 “
	Voting
	Stock
	” of a Person means capital stock of such Person
	of the class or classes pursuant to which the holders thereof have
	the general voting power to elect, or the general power to appoint,
	at least a majority of the board of directors, managers, trustees
	or other similar governing body of such Person (irrespective of
	whether or not at the time capital stock of any other class or
	classes shall have or might have voting power by reason of the
	happening of any contingency).
	 
	24.
	 
	Disclosure
	. Upon receipt or
	delivery by the Company of any notice in accordance with the terms
	of this Certificate of Designations, unless the Company has in good
	faith determined that the matters relating to such notice do not
	constitute material, non-public information relating to the Company
	or any of its Subsidiaries, the Company shall simultaneously with
	any such receipt or delivery publicly disclose such material,
	non-public information on a Current Report on Form 8-K or
	otherwise. In the event that the Company believes that a notice
	contains material, non-public information relating to the Company
	or any of its Subsidiaries, the Company so shall indicate to each
	Holder contemporaneously with delivery of such notice, and in the
	absence of any such indication, each Holder shall be allowed to
	presume that all matters relating to such notice do not constitute
	material, non-public information relating to the Company or its
	Subsidiaries.
	 
	* * * *
	*
	 
	IN
	WITNESS WHEREOF, the Corporation has caused this Certificate of
	Designations of Series L Convertible Preferred Stock of MabVax
	Therapeutics Holdings, Inc. to be signed by its President and Chief
	Executive Officer on this 16th day of October, 2017.
	 
	 
	By:
	/s/ J. David
	Hansen
	Name:
	J. David Hansen
	Title:
	President and Chief Executive Officer
	 
	 
	 
	 
	 
	EXHIBIT I
	 
	MABVAX THERAPEUTICS HOLDINGS, INC.
	CONVERSION NOTICE
	 
	Reference is made
	to the Certificate of Designations, Preferences and Rights of the
	Series L Convertible Preferred Stock of MabVax Therapeutics
	Holdings, Inc. (the “
	Certificate of Designations
	”). In
	accordance with and pursuant to the Certificate of Designations,
	the undersigned hereby elects to convert the number of shares of
	Series L Convertible Preferred Stock, $0.01 par value per share
	(the “
	Preferred
	Shares
	”), of MabVax Therapeutics Holdings, Inc., a
	Delaware corporation (the “
	Company
	”), indicated below into
	shares of common stock, $0.01 par value per share (the
	“
	Common Stock
	”),
	of the Company, as of the date specified below.
	 
	Date of
	Conversion:                                                                                                                                
	 
	Number
	of Preferred Shares to be
	converted:                                                                                                                                
	 
	Share
	certificate no(s). of Preferred Shares to be
	converted:                                                                                                                                
	 
	Tax ID
	Number (If
	applicable):                                                                                                                                
	 
	Conversion
	Price:_________________________________________________________
	 
	Number
	of shares of Common Stock to be
	issued:                                                                                                                                
	 
	Please
	issue the shares of Common Stock into which the Preferred Shares
	are being converted in the following name and to the following
	address:
	 
	Issue
	to:                                                                                     
	 
	 
	 
	Address:
	_________________________________________
	 
	Telephone Number:
	________________________________
	 
	Facsimile
	Number:                                                                                     
	 
	Holder:                                                                                     
	 
	By:                                                        
	 
	Title:                                                        
	 
	Dated:_____________________________
	 
	Account
	Number (if electronic book entry
	transfer):                                                                                                                                
	 
	Transaction Code
	Number (if electronic book entry
	transfer):                                                                                                                                
	 
	 
	EXHIBIT II
	 
	ACKNOWLEDGMENT
	 
	The
	Company hereby acknowledges this Conversion Notice and hereby
	directs
	[                                ]
	to issue the above indicated number of shares of Common Stock in
	accordance with the Irrevocable Transfer Agent Instructions dated
	__________, 201_ from the Company and acknowledged and agreed to by
	[                              ].
	 
	MABVAX
	THERAPEUTICS HOLDINGS, INC.
	 
	 
	Name:
	Title:
	 
	  Exhibit
	3.2
	 
	 
	CERTIFICATE OF CORRECTION
	OF
	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF
	THE
	0% SERIES L CONVERTIBLE PREFERRED STOCK
	OF
	MABVAX THERAPEUTICS HOLDINGS, INC.
	A Delaware Corporation
	 
	MabVax
	Therapeutics Holdings, Inc., a corporation organized and existing
	under the General Corporation Law of the State of Delaware (the
	“Company”), in accordance with the provisions of
	Section 103 thereof, DOES HEREBY CERTIFY:
	 
	1. The
	name of the Company is MabVax Therapeutics Holdings,
	Inc.
	 
	2. A
	Certificate of Designation for Series L Convertible Preferred Stock
	of the Corporation (the “Certificate of Designation”)
	was filed with the Secretary of State for the State of Delaware on
	October 16, 2017, and the Certificate of Designation requires
	correction as permitted by subsection (f) of Section 103 of the
	General Corporation Law of the State of Delaware.
	 
	3. The
	inaccuracy or defect of the Certificate of Designation is that the
	said Certificate of Designation inadvertently omitted a sentence
	relating to shareholder approval of conversions from Section 4
	“Conversion.”
	 
	4. The
	Certificate of Designation is corrected by replacing Section 4 in
	its entirety with the following:
	 
	4.
	 
	Conversion
	. Each Preferred
	Share shall be convertible into validly issued, fully paid and
	non-assessable shares of Common Stock (as defined below) on the
	terms and conditions set forth in this Section 4. Notwithstanding
	anything herein to the contrary, if the Company has not obtained
	the approval of its shareholders in accordance with the rules of
	the Nasdaq Stock Market LLC for the conversion of the Preferred
	Shares, then the Company may not issue upon conversion of the
	Preferred Shares any shares of Common Stock.
 
	 
	(a)
	           
	 
	Holder’s Conversion
	Right
	. Subject to the provisions of Section 4(e), at any
	time or times on or after the Initial Issuance Date, each Holder
	shall be entitled to convert any whole number of Preferred Shares
	into validly issued, fully paid and non-assessable shares of Common
	Stock in accordance with Section 4(c) at the Conversion Rate (as
	defined below).
 
	 
	(b)
	 
	Conversion Rate
	. The number of
	validly issued, fully paid and non-assessable shares of Common
	Stock issuable upon conversion of each Preferred Share pursuant to
	Section 4(a) shall be determined according to the following formula
	(the “
	Conversion
	Rate
	”):
	Base
	Amount
	Conversion
	Price
	 
	No fractional
	shares of Common Stock are to be issued upon the conversion of any
	Preferred Shares. If the issuance would result in the issuance of a
	fraction of a share of Common Stock, the Company shall round such
	fraction of a share of Common Stock up to the nearest whole
	share.
	 
	 
	 
	(c)
	 
	Mechanics of Conversion
	. The
	conversion of each Preferred Share shall be conducted in the
	following manner:
	 
	(i)
	 
	Holder’s Conversion
	. To
	convert a Preferred Share into validly issued, fully paid and
	non-assessable shares of Common Stock on any date (a
	“
	Conversion
	Date
	”), a Holder shall deliver (whether via facsimile
	or otherwise), for receipt on or prior to 11:59 p.m., New York
	time, on such date, a copy of an executed notice of conversion of
	the share(s) of Preferred Shares subject to such conversion in the
	form attached hereto as
	Exhibit I
	(the “
	Conversion
	Notice
	”) to the Company. If required by Section
	4(c)(vi), within five (5) Trading Days following a conversion of
	any such Preferred Shares as aforesaid, such Holder shall surrender
	to a nationally recognized overnight delivery service for delivery
	to the Company the original certificates representing the share(s)
	of Preferred Shares (the “
	Preferred Share Certificates
	”) so
	converted as aforesaid.
	 
	(ii)
	 
	Company’s Response
	. On or
	before the first (1
	st
	) Trading Day
	following the date of receipt of a Conversion Notice, the Company
	shall transmit by facsimile an acknowledgment of confirmation, in
	the form attached hereto as
	Exhibit II
	,
	of receipt of such Conversion Notice to such Holder and the
	Transfer Agent, which confirmation shall constitute an instruction
	to the Transfer Agent to process such Conversion Notice in
	accordance with the terms herein. On or before the second
	(2
	nd
	)
	Trading Day following the date of receipt by the Company of such
	Conversion Notice, the Company shall (1) provided that the Transfer
	Agent is participating in DTC Fast Automated Securities Transfer
	Program, credit such aggregate number of shares of Common Stock to
	which such Holder shall be entitled to such Holder’s or its
	designee’s balance account with DTC through its
	Deposit/Withdrawal at Custodian system, or (2) if the Transfer
	Agent is not participating in the DTC Fast Automated Securities
	Transfer Program, issue and deliver (via reputable overnight
	courier) to the address as specified in such Conversion Notice, a
	certificate, registered in the name of such Holder or its designee,
	for the number of shares of Common Stock to which such Holder shall
	be entitled. If the number of Preferred Shares represented by the
	Preferred Share Certificate(s) submitted for conversion pursuant to
	Section
	4(c)(vi)
	is
	greater than the number of Preferred Shares being converted, then
	the Company shall if requested by such Holder, as soon as
	practicable and in no event later than three (3) Trading Days after
	receipt of the Preferred Share Certificate(s) and at its own
	expense, issue and deliver to such Holder (or its designee) a new
	Preferred Share Certificate representing the number of Preferred
	Shares not converted.
	 
	(iii)
	 
	Record Holder
	. The Person or
	Persons entitled to receive the shares of Common Stock issuable
	upon a conversion of Preferred Shares shall be treated for all
	purposes as the record holder or holders of such shares of Common
	Stock on the Conversion Date.
	 
	 
	 
	(iv)
	 
	Company’s Failure to Timely
	Convert
	. If the Company shall fail, for any reason or for no
	reason, to issue to a Holder within three (3) Trading Days after
	the Company’s receipt of a Conversion Notice (whether via
	facsimile or otherwise) (the “
	Share Delivery Deadline
	”), a
	certificate for the number of shares of Common Stock to which such
	Holder is entitled and register such shares of Common Stock on the
	Company’s share register or to credit such Holder’s or
	its designee’s balance account with DTC for such number of
	shares of Common Stock to which such Holder is entitled upon such
	Holder’s conversion of any Preferred Shares (as the case may
	be) (a “
	Conversion
	Failure
	”), then, in addition to all other remedies
	available to such Holder, such Holder, upon written notice to the
	Company, may void its Conversion Notice with respect to, and retain
	or have returned (as the case may be) any Preferred Shares that
	have not been converted pursuant to such Holder’s Conversion
	Notice, provided that the voiding of a Conversion Notice shall not
	affect the Company’s obligations to make any payments which
	have accrued prior to the date of such notice pursuant to the terms
	of this Certificate of Designations or otherwise and (y) the
	Company shall pay in cash to such Holder on each day after such
	third (3
	rd
	) Trading Day that
	the issuance of such shares of Common Stock is not timely effected
	an amount equal to 1.5% of the product of (A) the aggregate number
	of shares of Common Stock not issued to such Holder on a timely
	basis and to which the Holder is entitled and (B) the Closing Sale
	Price of the Common Stock on the Trading Day immediately preceding
	the last possible date on which the Company could have issued such
	shares of Common Stock to the Holder without violating Section
	4(c). In addition to the foregoing, if within three (3) Trading
	Days after the Company’s receipt of a Conversion Notice
	(whether via facsimile or otherwise), the Company shall fail to
	issue and deliver a certificate to such Holder and register such
	shares of Common Stock on the Company’s share register or
	credit such Holder’s or its designee’s balance account
	with DTC for the number of shares of Common Stock to which such
	Holder is entitled upon such Holder’s conversion hereunder
	(as the case may be), and if on or after such third (3
	rd
	) Trading Day such
	Holder (or any other Person in respect, or on behalf, of such
	Holder) purchases (in an open market transaction or otherwise)
	shares of Common Stock to deliver in satisfaction of a sale by such
	Holder of all or any portion of the number of shares of Common
	Stock, or a sale of a number of shares of Common Stock equal to all
	or any portion of the number of shares of Common Stock, issuable
	upon such conversion that such Holder so anticipated receiving from
	the Company, then, in addition to all other remedies available to
	such Holder, the Company shall, within three (3) Business Days
	after such Holder’s request and in such Holder’s
	discretion, either (i) pay cash to such Holder in an amount equal
	to such Holder’s total purchase price (including brokerage
	commissions and other out-of-pocket expenses, if any) for the
	shares of Common Stock so purchased (including, without limitation,
	by any other Person in respect, or on behalf, of such Holder) (the
	“
	Buy-In Price
	”),
	at which point the Company’s obligation to so issue and
	deliver such certificate or credit such Holder’s balance
	account with DTC for the number of shares of Common Stock to which
	such Holder is entitled upon such Holder’s conversion
	hereunder (as the case may be) (and to issue such shares of Common
	Stock) shall terminate, or (ii) promptly honor its obligation to so
	issue and deliver to such Holder a certificate or certificates
	representing such shares of Common Stock or credit such
	Holder’s balance account with DTC for the number of shares of
	Common Stock to which such Holder is entitled upon such
	Holder’s conversion hereunder (as the case may be) and pay
	cash to such Holder in an amount equal to the excess (if any) of
	the Buy-In Price over the product of (A) such number of shares of
	Common Stock multiplied by (B) the lowest Closing Sale Price of the
	Common Stock on any Trading Day during the period commencing on the
	date of the applicable Conversion Notice and ending on the date of
	such issuance and payment under this clause (ii).
	 
	 
	 
	(v)
	 
	Pro Rata Conversion; Dispute
	.
	In the event the Company receives a Conversion Notice from more
	than one Holder for the same Conversion Date and the Company can
	convert some, but not all, of such Preferred Shares submitted for
	conversion, the Company shall convert from each Holder electing to
	have Preferred Shares converted on such date a pro rata amount of
	such Holder’s Preferred Shares submitted for conversion on
	such date based on the number of Preferred Shares submitted for
	conversion on such date by such Holder relative to the aggregate
	number of Preferred Shares submitted for conversion on such date.
	In the event of a dispute as to the number of shares of Common
	Stock issuable to a Holder in connection with a conversion of
	Preferred Shares, the Company shall issue to such Holder the number
	of shares of Common Stock not in dispute and resolve such dispute
	in accordance with Section 22.
	 
	(vi)
	 
	Book-Entry
	. Notwithstanding
	anything to the contrary set forth in this Section 4, upon
	conversion of any Preferred Shares in accordance with the terms
	hereof, no Holder thereof shall be required to physically surrender
	the certificate representing the Preferred Shares to the Company
	following conversion thereof unless (A) the full or remaining
	number of Preferred Shares represented by the certificate are being
	converted (in which event such certificate(s) shall be delivered to
	the Company as contemplated by this Section 4(c)(vi)) or (B) such
	Holder has provided the Company with prior written notice (which
	notice may be included in a Conversion Notice) requesting
	reissuance of Preferred Shares upon physical surrender of any
	Preferred Shares. Each Holder and the Company shall maintain
	records showing the number of Preferred Shares so converted by such
	Holder and the dates of such conversions or shall use such other
	method, reasonably satisfactory to such Holder and theCompany, so
	as not to require physical surrender of the certificate
	representing the Preferred Shares upon each such conversion. In the
	event of any dispute or discrepancy, such records of such Holder
	establishing the number of Preferred Shares to which the record
	holder is entitled shall be controlling and determinative in the
	absence of manifest error. A Holder and any transferee or assignee,
	by acceptance of a certificate, acknowledge and agree that, by
	reason of the provisions of this paragraph, following conversion of
	any Preferred Shares, the number of Preferred Shares represented by
	such certificate may be less than the number of Preferred Shares
	stated on the face thereof. Each certificate for Preferred Shares
	shall bear the following legend:
 
	 
	ANY
	TRANSFEREE OR ASSIGNEE OF THIS CERTIFICATE SHOULD CAREFULLY REVIEW
	THE TERMS OF THE CORPORATION’S CERTIFICATE OF DESIGNATIONS
	RELATING TO THE SHARES OF SERIES L PREFERRED STOCK REPRESENTED BY
	THIS CERTIFICATE, INCLUDING SECTION 4(c)(vi) THEREOF. THE NUMBER OF
	SHARES OF SERIES L PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE
	MAY BE LESS THAN THE NUMBER OF SHARES OF SERIES L PREFERRED STOCK
	STATED ON THE FACE HEREOF PURSUANT TO SECTION 4(c)(vi) OF THE
	CERTIFICATE OF DESIGNATIONS RELATING TO THE SHARES OF SERIES L
	PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE.
	 
	(d)
	 
	Taxes
	. The Company shall pay
	any and all documentary, stamp, transfer (but only in respect of
	the registered holder thereof), issuance and other similar taxes
	that may be payable with respect to the issuance and delivery of
	shares of Common Stock upon the conversion of Preferred
	Shares.
	 
	 
	 
	 
	(e)
	 
	Limitation on Beneficial
	Ownership
	. Notwithstanding anything to the contrary
	contained in this Certificate of Designations, the Preferred Shares
	held by a Holder shall not be convertible by such Holder, and the
	Company shall not effect any conversion of any Preferred Shares
	held by such Holder, to the extent (but only to the extent) that
	such Holder or any of its affiliates would beneficially own in
	excess of 4.99% (the “
	Maximum
	Percentage
	”) of the Common Stock. To the extent
	the above limitation applies, the determination of whether the
	Preferred Shares held by such Holder shall be convertible
	(vis-à-vis other convertible, exercisable or exchangeable
	securities owned by such Holder or any of its affiliates) and of
	which such securities shall be convertible, exercisable or
	exchangeable (as among all such securities owned by such Holder and
	its affiliates) shall, subject to such Maximum Percentage
	limitation, be determined on the basis of the first submission to
	the Company for conversion, exercise or exchange (as the case may
	be). No prior inability of a Holder to convert Preferred Shares, or
	of the Company to issue shares of Common Stock to such Holder,
	pursuant to this Section 4(e) shall have any effect on the
	applicability of the provisions of this Section 4(e) with
	respect to any subsequent determination of convertibility or
	issuance (as the case may be). For purposes of this Section 4(e),
	beneficial ownership and all determinations and calculations
	(including, without limitation, with respect to calculations of
	percentage ownership) shall be determined in accordance with
	Section 13(d) of the 1934 Act and the rules and regulations
	promulgated thereunder. The provisions of this Section 4(e) shall
	be implemented in a manner otherwise than in strict conformity with
	the terms of this Section 4(e) to correct this Section 4(e) (or any
	portion hereof) which may be defective or inconsistent with the
	intended Maximum Percentage beneficial ownership limitation herein
	contained or to make changes or supplements necessary or desirable
	to properly give effect to such Maximum Percentage limitation. The
	limitations contained in this Section 4(e) shall apply to a
	successor holder of Preferred Shares. The holders of Common Stock
	shall be third party beneficiaries of this Section 4(e) and the
	Company may not waive this Section 4(e). For any reason at any
	time, upon the written or oral request of a Holder, the Company
	shall within two (2) Business Days confirm orally and in writing to
	such Holder the number of shares of Common Stock then outstanding,
	including by virtue of any prior conversion or exercise of
	convertible or exercisable securities into Common Stock, including,
	without limitation, pursuant to this Certificate of Designations.
	By written notice to the Company, any Holder may increase or
	decrease the Maximum Percentage to any other percentage not in
	excess of 9.99% specified in such notice; provided that (i) any
	such increase will not be effective until the 61st day after such
	notice is delivered to the Company, and (ii) any such increase or
	decrease will apply only to such Holder sending such notice and not
	to any other Holder. For purposes hereof, in determining the number
	of outstanding shares of Common Stock, the Holder may rely on the
	number of outstanding shares of Common Stock as reflected in (1)
	the Company’s most recent Annual Report on Form 10-K,
	Quarterly Report on Form 10-Q, Current Report on Form 8-K or other
	public filing with the Securities and Exchange Commission, as the
	case may be, (2) a more recent public announcement by the Company,
	or (3) any other notice by the Company setting forth the number of
	shares of Common Stock outstanding. For any reason at any time,
	upon the written or oral request of a holder of Preferred Shares,
	the Company shall within three (3) Business Days confirm orally and
	in writing to such holder the number of shares of Common Stock then
	outstanding. In any case, the number of outstanding shares of
	Common Stock shall be determined after giving effect to the
	conversion or exercise of securities of the Company, including the
	Preferred Shares, by the Holder and its Affiliates since the date
	as of which such number of outstanding shares of Common Stock was
	reported, that in any event are convertible or exercisable, as the
	case may be, into shares of the Company’s Common Stock within
	60 days’ of such calculation and that are not subject to a
	limitation on conversion or exercise analogous to the limitation
	contained herein. The provisions of this paragraph shall be
	construed and implemented in a manner in accordance with Section
	13(d) of the 1934 Act and the rules and regulations promulgated
	thereunder.
	 
	 
	 
	[Signature
	Page Follows]
	 
	 
	 
	IN
	WITNESS WHEREOF, the Company has caused this Certificate of
	Correction to be executed as of the 18th day of October
	2017.
	 
| 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
| 
 
	MABVAX
	THERAPEUTICS HOLDINGS, INC.
 
	 
 
 | 
| 
 
	 
 
 | 
 
	 
 
 | 
| 
 
	By:
 
 
 | 
 
	 
 
 | 
 
	/s/ J. David
	Hansen
 
 
 | 
| 
 
	Name:
 
 | 
 
	 
 
 | 
 
	 J.
	David Hansen
 
 | 
| 
 
	Title:
 
 | 
 
	 
 
 | 
 
	 President
	and Chief Executive Officer
 
	 
 
 | 
 
	 
	 
	 
	Exhibit 10.1
	 
	EXCHANGE
	AGREEMENT
	 
	THIS
	EXCHANGE AGREEMENT (the “Agreement”), effective as
	October ____, 2017,
	 
	is
	made by and between MabVax Therapeutics Holdings, Inc., a Delaware
	corporation (“Company”), and the holder of Exchange
	Securities (as defined herein) signatory hereto (the
	“Holder”).
	 
	WHEREAS, the Holder
	owns shares of the Company’s Series ________
	1
	Convertible Preferred Stock as set forth
	on column 1 on Schedule A, annexed hereto (the “Exchange
	Securities”);
 
	 
	WHEREAS, the
	Company wishes to issue the Series L Preferred Shares (as such term
	is defined below) for the Exchange Securities as provided
	herein; and
	 
	WHEREAS, the
	Company has authorized a new series of convertible preferred stock
	of the Company designated as Series L Convertible Preferred Stock,
	$0.01 par value, the terms of which are set forth in the
	Certificate of Designation of Preferences, Rights and Limitations
	of 0% Series L Convertible Preferred Stock (the “Certificate
	of Designations”) in the form attached hereto as
	Exhibit A
	(together with any
	convertible preferred shares issued in replacement thereof in
	accordance with the terms thereof, the “Series L Preferred
	Shares”), which Series L Preferred Shares shall be
	convertible into Common Stock, in accordance with the terms of the
	Certificate of Designations;
	 
	WHEREAS, subject to
	the terms and conditions set forth in this Agreement and pursuant
	to Section 3(a)(9) of the Securities Act of 1933, as amended (the
	“Securities Act”), the Company desires to exchange with
	the Holder, and the Holder desires to exchange with the Company,
	the Exchange Securities for the Series L Preferred Shares (the
	“Exchange”).
	 
	NOW,
	THEREFORE, IN CONSIDERATION of the mutual covenants contained in
	this Agreement, and for other good and valuable consideration the
	receipt and adequacy of which are hereby acknowledged, the Company
	and Holder agree as follows:
	 
	1.
	 
	Terms of the Exchange
	. The
	Company and Holder agree that (i) the Holder will exchange the
	Exchange Securities and will relinquish any and all other rights it
	may have under the Exchange Securities in exchange for such number
	of Series L Preferred Shares as set forth in column 2 on
	Schedule A
	, annexed
	hereto.
	 
	2.
	 
	Closing
	. Upon satisfaction of
	the conditions set forth herein, a closing shall occur at the
	principal offices of the Company, or such other location as the
	parties shall mutually agree (the “Closing”). At
	Closing, Holder shall surrender the Exchange Securities and the
	Company shall deliver to Holder the Series L Preferred Shares, in
	such amounts as are set forth on
	Schedule A
	. Upon Closing, any
	and all obligations of the Company to Holder under the Exchange
	Securities shall be fully satisfied and Holder will have no
	remaining rights, powers, privileges, remedies or interests under
	the Exchange Securities.
	 
	3.
	 
	Further Assurances
	. Each party
	shall do and perform, or cause to be done and performed, all such
	further acts and things, and shall execute and deliver all such
	other agreements, certificates, instruments and documents, as any
	other party may reasonably request in order to carry out the intent
	and accomplish the purposes of this Agreement and the consummation
	of the transactions contemplated hereby.
	 
	4.
	 
	Representations and Warranties of the
	Holder
	. The Holder represents and warrants as of the date
	hereof and as of the closing to the Company as
	follows:
	 
	a.
	 
	Authorization; Enforcement
	. The
	Holder has the requisite corporate power and authority to enter
	into and to consummate the transactions contemplated by this
	Agreement, and otherwise to carry out its obligations hereunder and
	thereunder. The execution and delivery of the Agreement by the
	Holder and the consummation by it of the transactions contemplated
	hereby and thereby have been duly authorized by all necessary
	action on the part of the Holder and no further action is required
	by the Holder. This Agreement has been (or upon delivery will have
	been) duly executed by the Holder and, when delivered in accordance
	with the terms hereof, will constitute the valid and binding
	obligation of the Holder enforceable against the Holder in
	accordance with its terms, except: (i) as limited by general
	equitable principles and applicable bankruptcy, insolvency,
	reorganization, moratorium and other laws of general application
	affecting enforcement of creditors’ rights generally, (ii) as
	limited by laws relating to the availability of specific
	performance, injunctive relief or other equitable remedies and
	(iii) insofar as indemnification and contribution provisions may be
	limited by applicable law.
	 
	b.
	 
	Tax Advisors
	. The Holder has
	reviewed with its own tax advisors the U.S. federal, state, local
	and foreign tax consequences of this investment and the
	transactions contemplated by this Agreement. With respect to such
	matters, the Holder relies solely on such advisors and not on any
	statements or representations of the Company or any of its agents,
	written or oral. The Holder understands that it (and not the
	Company) shall be responsible for its own tax liability that may
	arise as a result of this investment or the transactions
	contemplated by this Agreement.
	 
	 
	 
	 
	c.
	 
	Information Regarding Holder
	.
	Holder is an “accredited investor”, as such term is
	defined in Rule 501 of Regulation D promulgated by the United
	States Securities and Exchange Commission (the
	“Commission”) under the Securities Act, is experienced
	in investments and business matters, has made investments of a
	speculative nature and has purchased securities of companies in
	private placements in the past and, with its representatives, has
	such knowledge and experience in financial, tax and other business
	matters as to enable the Holder to utilize the information made
	available by the Company to evaluate the merits and risks of and to
	make an informed investment decision with respect to the proposed
	purchase, which represents a speculative investment. Holder has the
	authority and is duly and legally qualified to purchase and own the
	Securities (as defined below). Holder is able to bear the risk of
	such investment for an indefinite period and to afford a complete
	loss thereof.
	 
	d.
	 
	Legend
	. The Holder understands
	that the Series L Preferred Shares and the shares of Common Stock
	issuable upon conversion of the Series L Preferred Shares (the
	“Conversion Shares” and, together with the Series L
	Preferred Shares, the “Securities”) when issued, shall
	be issued, pursuant to an exemption from registration or
	qualification under the Securities Act and applicable state
	securities laws, and except as set forth below, the Securities
	shall bear any legend as required by the “blue sky”
	laws of any state and a restrictive legend in substantially the
	following form (and a stop-transfer order may be placed against
	transfer of such stock certificates):
	 
	THE
	SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
	UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
	SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
	TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
	REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT
	OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF
	REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE
	COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II)
	UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE
	144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
	MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR
	OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
	SECURITIES.
	 
	e.
	 
	Removal of Legends
	.
	Certificates evidencing the Securities shall not be required to
	contain the legend set forth in Section 4(d) above or any
	other legend (i) while a registration statement covering the resale
	of such Securities is effective under the Securities Act, (ii)
	following any sale of such Shares pursuant to Rule 144 (as defined
	herein) (assuming the transferor is not an affiliate of the
	Company), (iii) if such Shares are eligible to be sold, assigned or
	transferred under Rule 144 and the Holder is not an affiliate of
	the Company (provided that the Holder provides the Company with
	reasonable assurances that such Shares are eligible for sale,
	assignment or transfer under Rule 144 which shall not include an
	opinion of the Holder’s counsel), (iv) in connection with a
	sale, assignment or other transfer (other than under Rule 144),
	provided that the Holder provides the Company with an opinion of
	counsel to the Holder, in a generally acceptable form, to the
	effect that such sale, assignment or transfer of the Securities may
	be made without registration under the applicable requirements of
	the Securities Act or (v) if such legend is not required under
	applicable requirements of the Securities Act (including, without
	limitation, controlling judicial interpretations and pronouncements
	issued by the Commission). If a legend is not required pursuant to
	the foregoing, the Company shall no later than three (3) business
	days following the delivery by the Holder to the Company or the
	transfer agent (with notice to the Company) of a legended
	certificate representing such Shares (endorsed or with stock powers
	attached, signatures guaranteed, and otherwise in form necessary to
	affect the reissuance and/or transfer, if applicable), together
	with any other deliveries from the Holder as may be required above
	in this Section 4(e), as directed by the Holder, either: (A)
	provided that the Company’s transfer agent is participating
	in the DTC Fast Automated Securities Transfer Program, credit the
	aggregate number of shares of Common Stock to which the Holder
	shall be entitled to the Holder’s or its designee’s
	balance account with DTC through its Deposit/Withdrawal at
	Custodian system or (B) if the Company’s transfer agent is
	not participating in the DTC Fast Automated Securities Transfer
	Program, issue and deliver (via reputable overnight courier) to the
	Holder, a certificate representing such Shares that is free from
	all restrictive and other legends, registered in the name of the
	Holder or its designee. The Company shall be responsible for any
	transfer agent fees or DTC fees with respect to any issuance of
	Shares or the removal of any legends with respect to any Shares in
	accordance herewith, including, but not limited to, fees for the
	opinions of counsel rendered to the transfer agent in connection
	with the removal of any legends.
	 
	f.
	 
	Restricted Securities
	. The
	Holder understands that: (i) the Securities have not been and are
	not being registered under the Securities Act or any state
	securities laws, and may not be offered for sale, sold, assigned or
	transferred unless (A) subsequently registered thereunder, (B) the
	Holder shall have delivered to the Company (if requested by the
	Company) an opinion of counsel to the Holder, in a form reasonably
	acceptable to the Company, to the effect that such Shares to be
	sold, assigned or transferred may be sold, assigned or transferred
	pursuant to an exemption from such registration, or (C) the Holder
	provides the Company with reasonable assurance that such Shares can
	be sold, assigned or transferred pursuant to Rule 144 or Rule 144A
	promulgated under the Securities Act (or a successor rule thereto)
	(collectively, “Rule 144”); (ii) any sale of the
	Securities made in reliance on Rule 144 may be made only in
	accordance with the terms of Rule 144, and further, if Rule 144 is
	not applicable, any resale of the Securities under circumstances in
	which the seller (or the Person through whom the sale is made) may
	be deemed to be an underwriter (as that term is defined in the
	Securities Act) may require compliance with some other exemption
	under the Securities Act or the rules and regulations of the
	Commission promulgated thereunder; and (iii) neither the Company
	nor any other Person is under any obligation to register the
	Securities under the Securities Act or any state securities laws or
	to comply with the terms and conditions of any exemption thereunder
	except as set forth herein.
	 
	 
	 
	 
	5.
	 
	Representations and Warranties of the
	Company
	. The Company hereby makes the following
	representations and warranties to the Holder:
	 
	a.
	 
	Authorization; Enforcement
	. The
	Company has the requisite corporate power and authority to enter
	into and to consummate the transactions contemplated by this
	Agreement and each of the other agreements entered into by the
	parties hereto in connection with the transactions contemplated by
	this Agreement (collectively, the “Exchange Documents”)
	and otherwise to carry out its obligations hereunder and
	thereunder.  The execution and delivery of this Agreement
	by the Company and the consummation by it of the transactions
	contemplated hereby and thereby have been duly authorized by all
	necessary action on the part of the Company and no further action
	is required by the Company, the Board of Directors of the Company
	or the Company’s stockholders in connection therewith,
	including, without limitation, the issuance of the Securities, and
	no further filing, consent, or authorization is required by the
	Company, its Board of Directors or its stockholders, subject to
	acceptance by the Nasdaq Capital Market of the LAS.  This
	Agreement and any Other Agreement (as defined herein) have been (or
	upon delivery will have been) duly executed by the Company and,
	when delivered in accordance with the terms hereof, will constitute
	the valid and binding obligation of the Company enforceable against
	the Company in accordance with its terms, except: (i) as limited by
	general equitable principles and applicable bankruptcy, insolvency,
	reorganization, moratorium and other laws of general application
	affecting enforcement of creditors’ rights generally, (ii) as
	limited by laws relating to the availability of specific
	performance, injunctive relief or other equitable remedies and
	(iii) insofar as indemnification and contribution provisions may be
	limited by applicable law.
	 
	b.
	 
	Organization and Qualification
	.
	Each of the Company and its subsidiaries (the
	“Subsidiaries”) are entities duly organized and validly
	existing and in good standing under the laws of the jurisdiction in
	which they are formed, and have the requisite power and
	authorization to own their properties and to carry on their
	business as now being conducted and as presently proposed to be
	conducted. Each of the Company and each of its Subsidiaries is duly
	qualified as a foreign entity to do business and is in good
	standing in every jurisdiction in which its ownership of property
	or the nature of the business conducted by it makes such
	qualification necessary, except to the extent that the failure to
	be so qualified or be in good standing would not have a Material
	Adverse Effect. As used in this Agreement, “Material Adverse
	Effect” means any material adverse effect on (i) the
	business, properties, assets, liabilities, operations (including
	results thereof), condition (financial or otherwise) or prospects
	of the Company or any Subsidiary, individually or taken as a whole,
	(ii) the transactions contemplated hereby or in any of the other
	Exchange Documents or (iii) the authority or ability of the Company
	to perform any of its obligations under any of the Exchange
	Documents. Other than its Subsidiaries, there is no Person (as
	defined below) in which the Company, directly or indirectly, owns
	capital stock or holds an equity or similar interest.
	“Person” means an individual, a limited liability
	company, a partnership, a joint venture, a corporation, a trust, an
	unincorporated organization, any other entity and any governmental
	entity or any department or agency thereof.
	 
	c.
	 
	No Conflict
	. The execution,
	delivery and performance of the Exchange Documents by the Company
	and the consummation by the Company of the transactions
	contemplated hereby and thereby (including, without limitation, the
	issuance of the Securities and reservation for issuance of the
	Conversion Shares) will not (i) result in a violation of the
	Certificate of Incorporation (as defined below) or other
	organizational documents of the Company or any of its Subsidiaries,
	any capital stock of the Company or any of its Subsidiaries or
	Bylaws (as defined below) of the Company or any of its
	Subsidiaries, (ii) conflict with, or constitute a default (or an
	event which with notice or lapse of time or both would become a
	default) under, or give to others any rights of termination,
	amendment, acceleration or cancellation of, any agreement,
	indenture or instrument to which the Company or any of its
	Subsidiaries is a party, or (iii) result in a violation of any law,
	rule, regulation, order, judgment or decree (including foreign,
	federal and state securities laws and regulations and the rules and
	regulations of the Principal Market applicable to the Company
	except, in the case of clause (ii) or (iii) above, to the extent
	such violations that could not reasonably be expected to have a
	Material Adverse Effect.
	 
	d.
	 
	No Consents
	. Neither the
	Company nor any Subsidiary is required to obtain any consent from,
	authorization or order of, or make any filing or registration with,
	any court, governmental agency or any regulatory or self-regulatory
	agency or any other Person in order for it to execute, deliver or
	perform any of its respective obligations under or contemplated by
	the Exchange Documents, in each case, in accordance with the terms
	hereof or thereof. All consents, authorizations, orders, filings
	and registrations which the Company or any Subsidiary is required
	to obtain pursuant to the preceding sentence have been obtained or
	effected on or prior to the date of this Agreement, and neither the
	Company nor any of its Subsidiaries is aware of any facts or
	circumstances which might prevent the Company or any of its
	Subsidiaries from obtaining or effecting any of the registration,
	application or filings contemplated by the Exchange Documents.
	Except as disclosed in the Company’s filings with the
	Commission (the “SEC Documents”), the Company is not in
	violation of the requirements of the Principal Market and has no
	knowledge of any facts or circumstances which could reasonably lead
	to delisting or suspension of the Common Stock in the foreseeable
	future. The Company has obtained or submitted all necessary
	consents and approvals from the Principal Market, including, if
	required, a LAS application covering the listing of the Conversion
	Shares with the Principal Market. In the event that the LAS has not
	been approved prior to the Closing, the Conversion Shares shall be
	subject to all limitations imposed by NASDAQ Listing Rule 5635 (d)
	until such time as shareholder approval of the issuance of
	Conversion Shares has been obtained.
	 
	 
	 
	 
	e.
	 
	Securities Law Exemptions
	.
	Assuming the accuracy of the representations and warranties of the
	Holder contained herein, the offer and issuance by the Company of
	the Securities is exempt from registration under the Securities
	Act. The offer and issuance of the Securities is exempt from
	registration under the Securities Act pursuant to the exemption
	provided by Section 3(a)(9) thereof. The Company covenants and
	represents to the Holder that neither the Company nor any of its
	Subsidiaries has received, anticipates receiving, has any agreement
	to receive or has been given any promise to receive any
	consideration from the Holder or any other Person in connection
	with the transactions contemplated by the Exchange
	Documents.
	 
	f.
	 
	Issuance of Securities
	. The
	issuance of the Series L Preferred Shares is duly authorized and
	upon issuance in accordance with the terms of the Exchange
	Documents shall be validly issued, fully paid and non-assessable
	and free from all taxes, liens, charges and other encumbrances with
	respect to the issue thereof. The issuance of the Conversion Shares
	is duly authorized and upon issuance in accordance with the terms
	of the Exchange Documents and Certificates of Designations shall be
	validly issued, fully paid and non-assessable and free from all
	taxes, liens, charges and other encumbrances with respect to the
	issue thereof.
	 
	g.
	 
	Transfer Taxes
	. As of the date
	of this Agreement, all share transfer or other taxes (other than
	income or similar taxes) which are required to be paid in
	connection with the issuance of the Series L Preferred Shares to be
	exchanged with the Holder hereunder will be, or will have been,
	fully paid or provided for by the Company, and all laws imposing
	such taxes will be or will have been complied with.
	 
	h.
	 
	Equity Capitalization
	. Except
	as disclosed in the SEC Documents: (i) none of the Company’s
	or any Subsidiary’s capital stock is subject to preemptive
	rights or any other similar rights or any liens or encumbrances
	suffered or permitted by the Company or any Subsidiary; (ii) there
	are no outstanding options, warrants, scrip, rights to subscribe
	to, calls or commitments of any character whatsoever relating to,
	or securities or rights convertible into, or exercisable or
	exchangeable for, any capital stock of the Company or any of its
	Subsidiaries, or contracts, commitments, understandings or
	arrangements by which the Company or any of its Subsidiaries is or
	may become bound to issue additional capital stock of the Company
	or any of its Subsidiaries or options, warrants, scrip, rights to
	subscribe to, calls or commitments of any character whatsoever
	relating to, or securities or rights convertible into, or
	exercisable or exchangeable for, any capital stock of the Company
	or any of its Subsidiaries, other than future potential issuances
	of additional shares of Common Stock to Sichenzia Ross Ference
	Kesner LLP for any future financings by the Company at a price per
	share less than $0.50, and the potential issuance to a certain lead
	investor in the Company’s prior financings of additional
	shares of common stock or convertible preferred stock to obtain the
	consent of the lead investor to future financings below $2.25 per
	share, with such issuance obligations to cease when the investor no
	longer owns any Series L Preferred Shares; (iii) there are no
	outstanding debt securities, notes, credit agreements, credit
	facilities or other agreements, documents or instruments evidencing
	indebtedness
	of the Company
	or any of its Subsidiaries or by which the Company or any of its
	Subsidiaries is or may become bound, other than that certain loan
	and security agreement with Oxford Finance LLC dated January 15,
	2016, and equipment leases and equipment financing in the ordinary
	course of business; (iv) there are no financing statements securing
	obligations in any amounts filed in connection with the Company or
	any of its Subsidiaries; (v) there are no agreements or
	arrangements under which the Company or any of its Subsidiaries is
	obligated to register the sale of any of their securities under the
	Securities Act other than various prior issuances of securities
	that have not been previously registered; (vi) there are no
	outstanding securities or instruments of the Company or any of its
	Subsidiaries which contain any redemption or similar provisions,
	and there are no contracts, commitments, understandings or
	arrangements by which the Company or any of its Subsidiaries is or
	may become bound to redeem a security of the Company or any of its
	Subsidiaries; (vii) there are no securities or instruments
	containing anti-dilution or similar provisions that will be
	triggered by the issuance of the Securities; (viii) neither the
	Company nor any Subsidiary has any stock appreciation rights or
	“phantom stock” plans or agreements or any similar plan
	or agreement; and (ix) neither the Company nor any of its
	Subsidiaries have any liabilities or obligations required to be
	disclosed in the SEC Documents which are not so disclosed in the
	SEC Documents, other than those incurred in the ordinary course of
	the Company’s or its Subsidiaries’ respective
	businesses and which, individually or in the aggregate, do not or
	could not have a Material Adverse Effect. The Company has furnished
	to the Holder true, correct and complete copies of the
	Company’s Certificate of Incorporation, as amended and as in
	effect on the date hereof (the “Certificate of
	Incorporation”), and the Company’s bylaws, as amended
	and as in effect on the date hereof (the “Bylaws”), and
	the terms of all securities convertible into, or exercisable or
	exchangeable for, shares of Common Stock and the material rights of
	the holders thereof in respect thereto that have not been disclosed
	in the SEC Documents.
	 
	i.
	 
	Shell Company Status
	. The
	Company is not and has not, for a period of at least two years,
	been an issuer identified in Rule 144(i)(1) of the Securities Act.
	The Company is, and has been for a period of at least 90 days,
	subject to the reporting requirements of Section 13 or Section
	15(d) of the Securities Exchange Act of 1934, as amended (the
	“Exchange Act”).
	 
	j.
	 
	Non-Affiliate.
	The Company is
	not, and is not an Affiliate of, and immediately after consummation
	of the transactions contemplated by the Exchange Documents, will
	not be or be an Affiliate of, an “investment company”
	within the meaning of the Investment Company Act of 1940, as
	amended. The Company shall conduct its business in a manner so that
	it will not become an “investment company” subject to
	registration under the Investment Company Act of 1940, as
	amended.
	 
	 
	 
	 
	6.
	 
	Additional Agreements of the
	Parties
	. The Company and the Holder agree as
	follows:
	 
	a.
	 
	Registration Rights
	. The
	Company shall file a “resale” registration statement
	with the Commission covering the Conversion Shares, so that such
	shares of common stock will be registered under the Securities Act.
	The Company will maintain the effectiveness of the
	“resale” registration statement from the effective date
	of the registration statement until all Registrable Securities (as
	defined in the Registration Rights Agreement, attached hereto as
	Exhibit B) covered by such registration statement have been sold,
	or may be sold without the requirement to be in compliance with
	Rule 144(c)(1) and otherwise without restriction or limitation
	pursuant to Rule 144.  The Company will use its
	reasonable best efforts to have such “resale”
	registration statement filed within ten (10) calendar days of the
	Closing and declared effective by the Commission as soon as
	possible and, in any event, by thirty (30) calendar days of the
	Filing Date (the “Effectiveness Date”). The Company is
	obligated to pay to the Holder a fee of one (1%) percent per month
	of the stated value of the Series L Preferred Shares, payable in
	cash, up to a maximum of six (6%) percent, on the Filing Date and
	the Effectiveness Date if the registration obligations set forth
	herein have not been met, and pro- rata for each month, or partial
	month, in excess of the Filing Date and/or
	the  Effectiveness Date that the registration statement
	has not been declared effective; provided, however, that the
	Company shall not be obligated to pay any such liquidated damages
	if the Company is unable to fulfill its registration obligations as
	a result of rules, regulations, positions or releases issued or
	actions taken by the Commission pursuant to its authority with
	respect to “Rule 415” or other rules, regulations,
	positions or releases issued or actions taken by the Commission,
	provided the Company registers at such time the maximum number of
	shares of Common Stock permissible upon consultation with the staff
	of the Commission.
	 
	b.
	 
	Rule 144 Acknowledgments
	. The
	Holder and the Company confirm that the Company has not received
	any consideration for the transactions contemplated by this
	Agreement. Pursuant to Rule 144 promulgated by the Commission
	pursuant to the Securities Act and the rules and regulations
	promulgated thereunder as such Rule 144 may be amended from time to
	time, or any similar rule or regulation hereafter adopted by the
	Commission having substantially the same effect as such Rule 144,
	the holding period of the Securities tacks back to
	___________.
	2
	The Company agrees not to take a
	position contrary to this paragraph and, at Closing, the
	Company’s counsel will deliver an opinion attesting to the
	acknowledgements contained in Section 5(d), Section 5(e) and this
	Section 6(b).
 
	 
	c.
	 
	Securities Laws Disclosure;
	Publicity
	.  The Company shall within three (3)
	Trading Days immediately following the Closing (a) issue a press
	release disclosing the material terms of the transactions
	contemplated hereby, and (b) file a Current Report on Form 8-K,
	including the Exchange Documents as exhibits thereto, with the
	Securities and Exchange Commission (the “Commission”)
	within the time required by the Exchange Act.  The
	Company and the Holder shall consult with each other in issuing any
	other press releases with respect to the transactions contemplated
	hereby, and neither the Company nor the Holder shall issue any such
	press release nor otherwise make any such public statement without
	the prior consent of the Company, with respect to any press release
	of the Holder, or without the prior consent of the Holder, with
	respect to any press release of the Company, which consent shall
	not unreasonably be withheld or delayed, except if such disclosure
	is required by law, in which case the disclosing party shall
	promptly provide the other party with prior notice of such public
	statement or communication. Notwithstanding the foregoing, the
	Company shall not publicly disclose the name of the Holder, or
	include the name of the Holder in any filing with the Commission or
	any regulatory agency or Trading Market, without the prior written
	consent of the Holder, except (a) as required by federal securities
	law in connection with the filing of final Exchange Documents
	(including signature pages thereto) with the Commission and (b) to
	the extent such disclosure is required by law or Trading Market
	regulations, in which case the Company shall provide the Holder
	with prior notice of such disclosure permitted under this Section
	6(c).
	 
	d.
	 
	Reserved
	.
	 
	e.
	 
	Material Non-Public
	Information
	. Except with respect to the material terms and
	conditions of the transactions contemplated by the Exchange
	Documents, the Company covenants and agrees that neither it, nor
	any other Person acting on its behalf, will provide Holder or its
	agents or counsel with any information that the Company believes
	constitutes material non-public information, unless prior thereto
	Holder shall have entered into a written agreement with the Company
	regarding the confidentiality and use of such information. The
	Company understands and confirms that Holder shall be relying on
	the foregoing covenant in effecting transactions in securities of
	the Company.
	 
	f.
	 
	Conversion Procedures
	. The form
	of Notice of Conversion included in the Certificate of Designations
	sets forth the totality of the procedures required of the Holder in
	order to convert the Series L Preferred Shares. No additional legal
	opinion, other information or instructions shall be required of the
	Holder to convert their Series L Preferred Shares. The Company
	shall honor conversions of the Series L Preferred Shares and shall
	deliver the Securities in accordance with the terms, conditions and
	time periods set forth in the Exchange Documents.
	 
	 
	 
	 
	g.
	 
	Reporting Obligations
	. Until
	the earliest of the time that (i) the Holder no longer owns
	Securities, the Company covenants to file all periodic reports with
	the Commission pursuant to Section 15(d) of the Exchange Act or
	alternatively, if registered under Section 12(b) or 12(g) of the
	1934 Act, maintain the registration of the Common Stock under
	Section 12(b) or 12(g) of the Exchange Act and to timely file (or
	obtain extensions in respect thereof and file within the applicable
	grace period) all reports required to be filed by the Company after
	the date hereof pursuant to the Exchange Act even if the Company is
	not then subject to the reporting requirements of the Exchange Act.
	At any time commencing on the Closing Date and ending at such time
	that all of the Securities may be sold without the requirement for
	the Company to be in compliance with Rule 144(c)(1) and otherwise
	without restriction or limitation pursuant to Rule 144, if the
	Company shall fail for any reason to satisfy the current public
	information requirement under Rule 144(c) (a “Public
	Information Failure”) then, in addition to Holder’s
	other available remedies, the Company shall pay to a Holder, in
	cash, as partial liquidated damages and not as a penalty, by reason
	of any such delay in or reduction of its ability to sell the
	Securities, an amount in cash equal to two percent (2.0%) of the
	aggregate Stated Value (as defined in the Certificates of
	Designations) of the Series L Preferred Shares and accrued interest
	held by such Holder on the day of a Public Information Failure and
	on every thirtieth (30th) day (pro-rated for periods totaling less
	than thirty days) thereafter until the earlier of (a) the date such
	Public Information Failure is cured and (b) such time that such
	public information is no longer required for the Holder to transfer
	the Conversion Shares pursuant to Rule 144. The payments to which a
	Holder shall be entitled pursuant to this Section 6(h) are referred
	to herein as “
	Public
	Information Failure Payments
	.” Public Information
	Failure Payments shall be paid on the earlier of (i) the last day
	of the calendar month during which such Public Information Failure
	Payments are incurred and (ii) the third (3rd) Business Day after
	the event or failure giving rise to the Public Information Failure
	Payments is cured. In the event the Company fails to make Public
	Information Failure Payments in a timely manner, such Public
	Information Failure Payments shall bear interest at the rate of one
	(1.0%) percent per month (prorated for partial months) until paid
	in full. Nothing herein shall limit Holder’s right to pursue
	actual damages for the Public Information Failure, and Holder shall
	have the right to pursue all remedies available to it at law or in
	equity including, without limitation, a decree of specific
	performance and/or injunctive relief.
	 
	h.
	 
	Form D; Blue Sky Filings
	. The
	Company agrees to timely file a Form D with respect to the
	Securities as required under Regulation D and to provide a copy
	thereof, promptly upon request of Holder. The Company shall take
	such action as the Company shall reasonably determine is necessary
	in order to obtain an exemption for, or to qualify the Securities
	for, sale to the Holder at the Closing under applicable securities
	or “Blue Sky” laws of the states of the United States,
	and shall provide evidence of such actions promptly upon request of
	Holder.
	 
	i.
	 
	Preservation of Corporate
	Existence
	. The Company shall preserve and maintain its
	corporate existence, rights, privileges and franchises in the
	jurisdiction of its incorporation, and qualify and remain
	qualified, as a foreign corporation in each jurisdiction in which
	such qualification is necessary in view of its business or
	operations and where the failure to qualify or remain qualified
	might reasonably have a Material Adverse Effect upon the financial
	condition, business or operations of the Company taken as a
	whole.
	 
	j.
	           
	 
	Shareholder
	Approval of Exchange
	. The Company shall hold a special
	meeting of the shareholders of the Company within 60 days of the
	date hereof, or at such other date that Broadridge Financial
	Solutions, Inc. recommends for timely processing of materials for
	the special meeting, at which the Company shall present to its
	shareholders a proposal for approval of the Exchange. In the event
	the Exchange is not approved at such shareholder meeting, the
	Company shall hold an additional shareholder meeting, within 90
	days of the first such shareholder meeting, at which the Company
	shall present to shareholders a proposal for approval of the
	Exchange. Until such time as the Exchange is approved by
	shareholders of the Company, the Company shall continue to hold
	shareholder meetings, each held within 90 days of the prior
	shareholder meeting. In the event that the Exchange has not been
	approved by shareholders of the Company within 60 days of the date
	hereof as a result of gross negligence by the Company (the
	“Shareholder Approval Deadline”), then, in addition to
	any other rights the Holder may have hereunder or under applicable
	law, the Company shall pay to the Holder on each 45-day anniversary
	of the Shareholder Approval Deadline (if such shareholder approval
	has not been obtained) until such shareholder approval has been
	obtained as partial liquidated damages and not as a penalty, equal
	to 1.0% of the aggregate Stated Value (as defined in the
	Certificate of Designations) of the Series L Preferred Shares for
	each month past the Shareholder Approval Deadline that the
	shareholder approval has not been obtained (pro-rated for any
	partial month in which such shareholder approval has not been
	obtained), provided, however, the Company shall not pay to the
	Holder more than 12.0% of the aggregate Stated Value (as defined in
	the Certificates of Designations) of the Series L Preferred Shares
	pursuant to this Agreement.
	7.
	 
	Miscellaneous
	.
	 
	a.
	 
	Successors and Assigns
	. This
	Agreement shall be binding upon and inure to the benefit of the
	parties and their respective successors and assigns.
	 
	b.
	 
	Governing Law; Jurisdiction; Waiver of
	Jury Trial
	. This Agreement shall be governed by and
	construed under the laws of the State of New York without regard to
	the choice of law principles thereof. Each party hereby irrevocably
	submits to the exclusive jurisdiction of the state and federal
	courts sitting in the State of New York located in The City of New
	York, Borough of Manhattan for the adjudication of any dispute
	hereunder or in connection herewith or therewith or with any
	transaction contemplated hereby or thereby, and hereby irrevocably
	waives any objection that such suit, action or proceeding is
	brought in an inconvenient forum or that the venue of such suit,
	action or proceeding is improper. Nothing contained herein shall be
	deemed to limit in any way any right to serve process in any manner
	permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT
	MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
	ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
	ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
	HEREBY.
	 
	c.
	 
	Severability
	. If any provision
	of this Agreement shall be invalid or unenforceable in any
	jurisdiction, such invalidity or unenforceability shall not affect
	the validity or enforceability of the remainder of this Agreement
	in that jurisdiction or the validity or enforceability of any
	provision of this Agreement in any other jurisdiction.
	 
	 
	 
	 
	d.
	 
	Counterparts/Execution
	. This
	Agreement may be executed in two or more identical counterparts,
	all of which shall be considered one and the same agreement and
	shall become effective when counterparts have been signed by each
	party and delivered to the other party. In the event that any
	signature is delivered by facsimile transmission or by an e-mail
	which contains an electronic file of an executed signature page,
	such signature page shall create a valid and binding obligation of
	the party executing (or on whose behalf such signature is executed)
	with the same force and effect as if such facsimile or electronic
	file signature page (as the case may be) were an original
	thereof.
	 
	e.
	 
	Notices
	. Any notice or
	communication permitted or required hereunder shall be in writing
	and shall be deemed sufficiently given if hand-delivered or sent
	(i) postage prepaid by registered mail, return receipt requested,
	or (ii) by facsimile, to the respective parties as set forth below,
	or to such other address as either party may notify the other in
	writing.
	 
| 
 
	If to
	the Company, to:
 
 | 
 
	MabVax
	Therapeutics Holdings, Inc.
 
 | 
| 
 
	 
 
 | 
 
	11535
	Sorrento Valley Road, Suite 400
 
 | 
| 
 
	 
 
 | 
 
	San
	Diego, CA 92121
 
 | 
| 
 
	 
 
 | 
 
	Attention:  Chief
	Executive Officer
 
 | 
 
	 
	If to
	Holder, to the address set forth on the signature page of the
	Holder.
	 
	f.
	 
	Expenses
	. The parties hereto
	shall pay their own costs and expenses in connection herewith,
	provided, however the Company shall pay all costs of registration
	under the Securities Act including any Rule 144 opinion
	costs.
	 
	g.
	 
	Entire Agreement; Amendments
	.
	This Agreement constitutes the entire agreement between the parties
	with regard to the subject matter hereof and thereof, superseding
	all prior agreements or understandings, whether written or oral,
	between or among the parties. This Agreement may be amended,
	modified, superseded, cancelled, renewed or extended, and the terms
	and conditions hereof may be waived, only by a written instrument
	signed by all parties, or, in the case of a waiver, by the party
	waiving compliance. Except as expressly stated herein, no delay on
	the part of any party in exercising any right, power or privilege
	hereunder shall operate as a waiver thereof, nor shall any waiver
	on the part of any party of any right, power or privilege hereunder
	preclude any other or future exercise of any other right, power or
	privilege hereunder.
	 
	h.
	 
	Headings
	. The headings used in
	this Agreement are used for convenience only and are not to be
	considered in construing or interpreting this
	Agreement.
	 
	i.
	 
	Independent Nature of the
	Holder’s Obligations and Rights
	. The obligations of
	the Holder under the Exchange Documents are several and not joint
	with the obligations of any other holder of Exchange Securities
	(each, an “Other Holder”) under any other agreement
	(each, an “Other Agreement”), and the Holder shall not
	be responsible in any way for the performance of the obligations of
	any Other Holders under any Other Agreement. Nothing contained
	herein or in any Other Agreement, and no action taken by the Holder
	pursuant hereto or any Other Holder pursuant to any Other
	Agreement, shall be deemed to constitute the Holder or any Other
	Holder as, and the Company acknowledges that the Holder and the
	Other Holders do not so constitute, a partnership, an association,
	a joint venture or any other kind of group or entity, or create a
	presumption that the Holder and any Other Holder are in any way
	acting in concert or as a group or entity with respect to such
	obligations or the transactions contemplated by the Exchange
	Documents, any other agreement or any matters, and the Company
	acknowledges that the Holder and the Other Holders are not acting
	in concert or as a group or entity, and the Company shall not
	assert any such claim, with respect to such obligations or the
	transactions contemplated by the Exchange Documents and any Other
	Agreement. The decision of the Holder to acquire the Securities
	pursuant to the Exchange Documents has been made by the Holder
	independently of any Other Holder. The Holder acknowledges that no
	Other Holder has acted as agent for the Holder in connection with
	the Holder making its acquisition hereunder and that no Other
	Holder will be acting as agent of the Holder in connection with
	monitoring the Holder’s Securities or enforcing its rights
	under the Exchange Documents. The Company and the Holder confirm
	that the Holder has independently participated with the Company in
	the negotiation of the transaction contemplated hereby with the
	advice of its own counsel and advisors. The Holder shall be
	entitled to independently protect and enforce its rights,
	including, without limitation, the rights arising out of this
	Agreement or out of any of the Other Agreements, and it shall not
	be necessary for any Other Holder to be joined as an additional
	party in any proceeding for such purpose. To the extent that any of
	the Other Holders and the Company enter into the same or similar
	documents, all such matters are solely in the control of the
	Company, not the action or decision of the Holder, and would be
	solely for the convenience of the Company
	 
	and not because it was required or
	requested to do so by the Holder or any Other Holder. For
	clarification purposes only and without implication that the
	contrary would otherwise be true, the transactions contemplated by
	the Exchange Documents include only the transaction between the
	Company and the Holder and do not include any other transaction
	between the Company and any Other Holder
	.
	 
	j
	.
	Shareholder Approval of
	Exchange
	. The Company shall hold a special meeting of the
	shareholders of the Company within 60 days of the date hereof, or
	at such other date that Broadridge Financial Solutions, Inc.
	recommends for timely processing of materials for the special
	meeting, at which the Company shall present to its shareholders a
	proposal for approval of the Exchange. In the event the Exchange is
	not approved at such shareholder meeting, the Company shall hold an
	additional shareholder meeting, within 90 days of the first such
	shareholder meeting, at which the Company shall present to
	shareholders a proposal for approval of the Exchange. Until such
	time as the Exchange is approved by shareholders of the Company,
	the Company shall continue to hold shareholder meetings, each held
	within 90 days of the prior shareholder meeting. In the event that
	the Exchange has not been approved by shareholders of the Company
	within 60 days of the date hereof as a result of gross negligence
	by the Company (the “Shareholder Approval Deadline”),
	then, in addition to any other rights the Holder may have hereunder
	or under applicable law, the Company shall pay to the Holder on
	each 45-day anniversary of the Shareholder Approval Deadline (if
	such shareholder approval has not been obtained) until such
	shareholder approval has been obtained as partial liquidated
	damages and not as a penalty, equal to 1.0% of the aggregate Stated
	Value (as defined in the Certificate of Designations) of the Series
	L Preferred Shares for each month past the Shareholder Approval
	Deadline that the shareholder approval has not been obtained
	(pro-rated for any partial month in which such shareholder approval
	has not been obtained), provided, however, the Company shall not
	pay to the Holder more than 12.0% of the aggregate Stated Value (as
	defined in the Certificates of Designations) of the Series L
	Preferred Shares pursuant to this Agreement.
	 
	 
	 
	 
	k.
	 
	Pledge of Securities
	. The
	Company acknowledges and agrees that the Securities may be pledged
	by the Holder in connection with a bona fide margin agreement or
	other loan or financing arrangement that is secured by the
	Securities. The pledge of Securities shall not be deemed to be a
	transfer, sale or assignment of the Securities hereunder, and if
	the Holder effects a pledge of Securities it shall not be required
	to provide the Company with any notice thereof or otherwise make
	any delivery to the Company pursuant to this Agreement or any Other
	Agreement. The Company hereby agrees to execute and deliver such
	documentation as a pledgee of the Securities may reasonably request
	in connection with a pledge of the Securities to such pledgee by
	the Holder.
	 
	l.
	 
	Separate Counsel
	. Each party
	hereto represents and agrees with each other that it has been
	represented by or had the opportunity to be represented by,
	independent counsel of its own choosing, and that it has had the
	full right and opportunity to consult with its respective
	attorney(s), that to the extent, if any, that it desired, it
	availed itself of this right and opportunity, that it or its
	authorized officers (as the case may be) have carefully read and
	fully understand this Agreement in its entirety and have had it
	fully explained to them by such party's respective counsel, that
	each is fully aware of the contents thereof and its meaning, intent
	and legal effect, and that it or its authorized officer (as the
	case may be) is competent to execute this Agreement and has
	executed this Agreement free from coercion, duress or undue
	influence. By their execution of this Agreement, the Company, on
	the one hand, and the Holder, on the other hand, hereby waive any
	actual or perceived conflict(s) of interest in connection with any
	prior, existing and any future representation or other
	relationships between the Company’s counsel and the Company
	or the Company’s counsel and the Holder, and that neither the
	Company nor the Holder has requested additional information;
	further the Holder and the Company acknowledge that Company counsel
	and members thereof maintain securities holdings in the Company
	which may include Exchange Securities, and may in the future
	acquire or dispose of additional securities or investments of the
	Company.
	 
	(Signature
	Pages Follow)
	 
	 
	IN
	 
	WITNESS WHEREOF, the parties have
	caused this Agreement to be duly executed as of the day and year
	first above written.
	 
	MABVAX THERAPEUTICS HOLDINGS, INC.
	  
	 
	By:____________________________________
	Name:
	J. David Hansen
	Title:
	President and Chief Executive Officer
	Date:_________________
	 
	HOLDER
	 
	____________________________________
	Name:
	Title:
	Date:_________________
	 
	 
	 
	 
	 
	Schedule A
	 
| 
 
	 
 
 | 
 
	(1)
 
 | 
 
	(2)
 
 | 
| 
 
	Name
 
 | 
 
	Shares of Series ___ Convertible Preferred Stock
 
 | 
 
	Shares of Series L
 
	Convertible Preferred Stock
 
 | 
| 
 
	 
 
	 
 
	 
 
	 
 
	 
 
	 
 
 | 
 
	 
 
 | 
 
	 
 
 | 
 
	 
	 
	 
	 
	Exhibit A
	 
	FORM OF
	CERTIFICATE OF DESIGNATION OF PREFERENCES,
	RIGHTS AND LIMITATIONS
	OF
	0% SERIES L CONVERTIBLE PREFERRED STOCK
	 
	 
	 
	 
	Exhibit B
	 
	FORM OF
	REGISTRATION RIGHTS AGREEMENT
	 
	Exhibit 10.2
	 
	REGISTRATION RIGHTS AGREEMENT
	 
	THIS
	REGISTRATION RIGHTS AGREEMENT (this “
	Agreement
	”) is made as of
	October ___, 2017, by and among the undersigned corporation (the
	“
	Company
	”), and each
	signatory hereto (each, an “
	Investor
	” and
	collectively, the “
	Investors
	”).
	 
	R E C I T A L S
	 
	WHEREAS, the
	Company and the Investors are parties to the Exchange Agreements
	(the “
	Exchange
	Agreements
	”), dated as of the date hereof, as such may
	be amended and supplemented from time to time;
	 
	WHEREAS, the
	Investors’ obligations under the Exchange Agreements are
	conditioned upon certain registration rights under the Securities
	Act of 1933, as amended (the “
	Securities Act
	”);
	and
	 
	WHEREAS, the
	Investors and the Company desire to provide for the rights of
	registration under the Securities Act as are provided herein upon
	the execution and delivery of this Agreement by such Investors and
	the Company.
	 
	NOW,
	THEREFORE, in consideration of the promises, covenants and
	conditions set forth herein, the parties hereto hereby agree as
	follows:
	 
	1.
	 
	Registration
	Rights
	.
	 
	 1.1
	 
	Definitions
	. As used in this
	Agreement, the following terms shall have the meanings set forth
	below:
 
	 
	(a)
	 
	“
	Commission
	” means the
	United States Securities and Exchange Commission.
	 
	(b)
	 
	“
	Common Stock
	” means the
	Company’s common stock, par value $0.01 per
	share.
	 
	(c)
	 
	“
	Effectiveness Date
	” means
	the date that is thirty (30) days after the Trigger
	Date.
	 
	(d)
	 
	“
	Exchange Act
	” means the
	Securities Exchange Act of 1934, as amended.
	 
	(e)
	 
	“
	Filing Date
	” means the
	date that is ten (10) days after the Trigger Date.
	 
	(f)
	 
	“
	Investor
	” means any
	person owning Registrable Securities who becomes party to this
	Agreement by executing a counterpart signature page hereto, or
	other agreement in writing to be bound by the terms hereof, which
	is accepted by the Company.
	 
	(g)
	 
	The terms
	“
	register
	,”
	“registered
	” and
	“
	registration
	” refer to a
	registration effected by preparing and filing a registration
	statement or similar document in compliance with the Securities
	Act, and the declaration or ordering of effectiveness of such
	registration statement or document.
	 
	(h)
	 
	“
	Registrable Securities
	”
	means 100% of the Shares;
	provided
	,
	however
	, that Registrable
	Securities shall not include any securities of the Company that
	have previously been registered and remain subject to a currently
	effective registration statement or which have been sold to the
	public either pursuant to a registration statement or Rule
	144.
	 
	(i)
	 
	“
	Rule 144
	” means Rule 144
	as promulgated by the Commission under the Securities Act, as such
	Rule may be amended from time to time, or any similar successor
	rule that may be promulgated by the Commission.
	 
	 
	 
	(j)
	 
	“
	Rule 415
	” means Rule 415
	as promulgated by the Commission under the Securities Act, as such
	Rule may be amended from time to time, or any similar successor
	rule that may be promulgated by the Commission.
	 
	(k)
	 
	“
	Shares
	” means the shares
	of Common Stock issuable upon conversion of the shares of Series L
	Preferred Stock of the Company (the “
	Series L Preferred
	Shares
	”) issued pursuant to the
	Exchange
	Agreements.
	 
	(l)
	 
	“
	Trigger Date
	” means the
	closing date of the Exchange Agreements.
	 
	 1.2
	 
	      
	Company
	Registration
	.
	 
	(a)
	 
	On or prior to the
	Filing Date, the Company shall prepare and file with the Commission
	a resale registration statement covering the Registrable Securities
	for an offering to be made on a continuous basis pursuant to Rule
	415. The resale registration statement shall be on Form S-1 or, if
	the Company is so eligible, on Form S-3 (except if the Company is
	not then eligible to register for resale the Registrable Securities
	on Form S-1 or Form S-3, as the case may be, in which case such
	registration shall be on another appropriate form in accordance
	herewith) and shall contain (unless otherwise directed by Investors
	holding an aggregate of at least 60% of the Registrable Securities
	on an “as converted” and “as exercised”
	basis) substantially the “
	Plan of Distribution
	”
	attached hereto as
	Annex
	A
	. The Company shall cause the registration statement to
	become effective and remain effective as provided herein. The
	Company shall use its reasonable best efforts to cause the
	registration statement to be declared effective under the
	Securities Act as soon as possible and, in any event, by the
	Effectiveness Date. The Company shall use its reasonable best
	efforts to keep the registration statement continuously effective
	under the Securities Act until all Registrable Securities covered
	by such registration statement have been sold, or may be sold
	without the requirement to be in compliance with Rule 144(c)(1) and
	otherwise without restriction or limitation pursuant to Rule 144,
	as determined by the counsel to the Company (the
	“
	Effectiveness
	Period
	”).
	 
	(b)
	 
	The Company shall
	pay to the Investors a fee of one (1%) percent per month of the
	aggregate Stated Value (as defined in the Certificate of
	Designation of Preferences, Rights and Limitations of 0% Series L
	Convertible Preferred Stock of the Series L Preferred Shares
	payable in cash, up to a maximum of six (6%) percent, if on the
	Filing Date and/or the Effectiveness Date the registration
	obligations set forth herein have not been met, and pro- rata for
	each month, or partial month, in excess of the Filing Date and/or
	the Effectiveness Date that the registration statement has not been
	declared effective; provided, however, that the Company shall not
	be obligated to pay any such liquidated damages if the Company is
	unable to fulfill its registration obligations as a result of
	rules, regulations, positions or releases issued or actions taken
	by the Commission pursuant to its authority with respect to
	“Rule 415” or other rules, regulations, positions or
	releases issued or actions taken by the Commission, provided the
	Company registers at such time the maximum number of shares of
	Common Stock permissible upon consultation with the staff of the
	Commission. If during the Effectiveness Period, the number of
	Registrable Securities at any time exceeds 100% of the number of
	shares of Common Stock then registered in a registration statement,
	the Company shall file as soon as reasonably practicable an
	additional registration statement covering the resale of not less
	than the number of such Registrable Securities.
	 
	(c)
	 
	The Company shall
	bear and pay all expenses incurred in connection with any
	registration, filing or qualification of Registrable Securities
	with respect to the registrations pursuant to this Section 1.2 for
	each Investor, including (without limitation) all registration,
	filing and qualification fees, printer’s fees, accounting
	fees and fees and disbursements of counsel for the Company, but
	excluding any brokerage or underwriting fees, discounts and
	commissions relating to Registrable Securities and fees and
	disbursements of counsel for the Investors.
	 
	 
	 
	(d)
	 
	If at any time
	during the Effectiveness Period there is not an effective
	Registration Statement covering all of the Registrable Securities,
	then the Company shall notify each Investor in writing at least
	fifteen (15) days prior to the filing of any registration statement
	under the Securities Act, in connection with a public offering of
	shares of Common Stock (including, but not limited to, registration
	statements relating to secondary offerings of securities of the
	Company but excluding any registration statements (i) on Form S-4
	or S-8 (or any successor or substantially similar form), or of any
	employee stock option, stock purchase or compensation plan or of
	securities issued or issuable pursuant to any such plan, or a
	dividend reinvestment plan, (ii) otherwise relating to any
	employee, benefit plan or corporate reorganization or other
	transactions covered by Rule 145 promulgated under the Securities
	Act, (iii) on any registration form which does not permit secondary
	sales or does not include substantially the same information as
	would be required to be included in a registration statement
	covering the resale of the Registrable Securities. In the event an
	Investor desires to include in any such registration statement all
	or any part of the Registrable Securities held by such Investor,
	the Investor shall within ten (10) days after the above-described
	notice from the Company, so notify the Company in writing,
	including the number of such Registrable Securities such Investor
	wishes to include in such registration statement. If an Investor
	decides not to include all of its Registrable Securities in any
	registration statement thereafter filed by the Company such
	Investor shall nevertheless continue to have the right to include
	any Registrable Securities in any subsequent registration statement
	or registration statements as may be filed by the Company with
	respect to the offering of the securities, all upon the terms and
	conditions set forth herein.
	 
	 1.3
	 
	Obligations
	of the Company
	. Whenever required under this Section 1 to
	effect the registration of any Registrable Securities, the Company
	shall, as expeditiously as reasonably possible:
	 
	(a)
	 
	Prepare and file
	with the Commission a registration statement with respect to such
	Registrable Securities and use its reasonable best efforts to cause
	such registration statement to become effective and to keep such
	registration statement effective during the Effectiveness
	Period;
	 
	(b)
	 
	Prepare and file
	with the Commission such amendments and supplements to such
	registration statement and the prospectus used in connection with
	such registration statement as may be necessary to comply with the
	provisions of the Securities Act with respect to the disposition of
	all securities covered by such registration statement;
	 
	(c)
	 
	Furnish to the
	Investors such numbers of copies of a prospectus, including a
	preliminary prospectus, in conformity with the requirements of the
	Securities Act, and such other documents as they may reasonably
	request in order to facilitate the disposition of Registrable
	Securities owned by them (provided that the Company would not be
	required to print such prospectuses if readily available to
	Investors from any electronic service, such as on the EDGAR filing
	database maintained at www.sec.gov);
	 
	(d)
	 
	Use its reasonable
	best efforts to register and qualify the securities covered by such
	registration statement under such other securities’ or blue
	sky laws of such jurisdictions as shall be reasonably requested by
	the Investors; provided that the Company shall not be required in
	connection therewith or as a condition thereto to qualify to do
	business or to file a general consent to service of process in any
	such states or jurisdictions;
	 
	(e)
	 
	In the event of any
	underwritten public offering, enter into and perform its
	obligations under an underwriting agreement, in usual and customary
	form, with the managing underwriter(s) of such offering (each
	Investor participating in such underwriting shall also enter into
	and perform its obligations under such an agreement);
	 
	(f)
	 
	Promptly notify
	each Investor holding Registrable Securities covered by such
	registration statement at any time when a prospectus relating
	thereto is required to be delivered under the Securities Act,
	within one business day, (i) of the effectiveness of such
	registration statement, or (ii) of the happening of any event as a
	result of which the prospectus included in such registration
	statement, as then in effect, includes an untrue statement of a
	material fact or omits to state a material fact required to be
	stated therein or necessary to make the statements therein not
	misleading in the light of the circumstances then
	existing;
	 
	(g)
	 
	Cause all such
	Registrable Securities registered pursuant hereto to be listed on
	each securities exchange or nationally recognized quotation system
	on which similar securities issued by the Company are then listed;
	and
	 
	 
	 
	(h)
	 
	Provide a transfer
	agent and registrar for all Registrable Securities registered
	pursuant hereunder and a CUSIP number for all such Registrable
	Securities, in each case not later than the effective date of such
	registration.
	 
	 1.4
	 
	Furnish
	Information
	. It shall be a condition precedent to the
	Company’s obligations to take any action pursuant to this
	Section 1 with respect to the Registrable Securities of any selling
	Investor that such Investor shall furnish to the Company such
	information regarding such Investor, the Registrable Securities
	held by such Investor, and the intended method of disposition of
	such securities in the form attached to this Agreement as Annex B,
	or as otherwise reasonably required by the Company or the managing
	underwriters, if any, to effect the registration of such
	Investor’s Registrable Securities.
	 
	 1.5
	 
	Delay
	of Registration
	. No Investor shall have any right to obtain
	or seek an injunction restraining or otherwise delaying any such
	registration as the result of any controversy that might arise with
	respect to the interpretation or implementation of this Section
	1.
	 
	 1.6
	 
	Indemnification
	.
	 
	(a)
	 
	To the extent
	permitted by law, the Company will indemnify and hold harmless each
	Investor, any underwriter (as defined in the Securities Act) for
	such Investor and each person, if any, who controls such Investor
	or underwriter within the meaning of the Securities Act or the
	Exchange Act, against any losses, claims, damages or liabilities
	(joint or several) to which any of the foregoing persons may become
	subject under the Securities Act, the Exchange Act or other federal
	or state securities law, insofar as such losses, claims, damages or
	liabilities (or actions in respect thereof) arise out of or are
	based upon any of the following statements, omissions or violations
	(collectively, a “
	Violation
	”): (i) any
	untrue statement or alleged untrue statement of a material fact
	contained in a registration statement, including any preliminary
	prospectus or final prospectus contained therein or any amendments
	or supplements thereto (collectively, the “
	Filings
	”), (ii) the
	omission or alleged omission to state in the Filings a material
	fact required to be stated therein, or necessary to make the
	statements therein not misleading, or (iii) any violation or
	alleged violation by the Company of the Securities Act, the
	Exchange Act, any state securities law or any rule or regulation
	promulgated under the Securities Act, the Exchange Act or any state
	securities law; and the Company will pay any legal or other
	expenses reasonably incurred by any person to be indemnified
	pursuant to this Section 1.6(a) in connection with investigating or
	defending any such loss, claim, damage, liability or action;
	provided
	,
	however
	, that the
	indemnity agreement contained in this Section 1.6(a) shall not
	apply to amounts paid in settlement of any such loss, claim,
	damage, liability or action if such settlement is effected without
	the consent of the Company (which consent shall not be unreasonably
	withheld), nor shall the Company be liable in any such case for any
	such loss, claim, damage, liability or action to the extent that it
	arises out of or is based upon a Violation that occurs in reliance
	upon and in conformity with written information furnished expressly
	for use in connection with such registration by any such Investor,
	underwriter or controlling person.
	 
	(b)
	 
	To the extent
	permitted by law, each Investor will indemnify and hold harmless
	the Company, each of its directors, each of its officers who has
	signed the registration statement, each person, if any, who
	controls the Company within the meaning of the Securities Act or
	the Exchange Act, any underwriter, any other Investor selling
	securities in such registration statement and any controlling
	person of any such underwriter or other Investor, against any
	losses, claims, damages or liabilities (joint or several) to which
	any of the foregoing persons may become subject under the
	Securities Act, the Exchange Act or other federal or state
	securities law, insofar as such losses, claims, damages or
	liabilities (or actions in respect thereto) arise out of or are
	based upon any Violation, in each case to the extent (and only to
	the extent) that such Violation occurs in reliance upon and in
	conformity with written information furnished by such Investor
	expressly for use in connection with such registration; and each
	such Investor will pay any legal or other expenses reasonably
	incurred by any person to be indemnified pursuant to this Section
	1.6(b) in connection with investigating or defending any such loss,
	claim, damage, liability or action;
	provided
	,
	however
	, that the indemnity
	agreement contained in this Section 1.6(b) shall not apply to
	amounts paid in settlement of any such loss, claim, damage,
	liability or action if such settlement is effected without the
	consent of the Investor (which consent shall not be unreasonably
	withheld);
	provided
	,
	however
	, in no event shall any
	indemnity under this subsection 1.6(b) exceed the net proceeds
	received by such Investor upon the sale of the Registrable
	Securities giving rise to such indemnification
	obligation.
	 
	 
	 
	(c)
	 
	Promptly after
	receipt by an indemnified party under this Section 1.6 of notice of
	the commencement of any action (including any governmental action),
	such indemnified party will, if a claim in respect thereof is to be
	made against any indemnifying party under this Section 1.6, deliver
	to the indemnifying party a written notice of the commencement
	thereof and the indemnifying party shall have the right to
	participate in, and, to the extent the indemnifying party so
	desires, jointly with any other indemnifying party similarly
	noticed, to assume the defense thereof with counsel mutually
	satisfactory to the parties;
	provided
	,
	however
	, that an indemnified
	party (together with all other indemnified parties that may be
	represented without conflict by one counsel) shall have the right
	to retain one separate counsel, with the fees and expenses to be
	paid by the indemnifying party, if representation of such
	indemnified party by the counsel retained by the indemnifying party
	would be inappropriate due to actual or potential differing
	interests between such indemnified party and any other party
	represented by such counsel in such proceeding. The failure to
	deliver written notice to the indemnifying party within a
	reasonable time of the commencement of any such action, if
	materially prejudicial to its ability to defend such action, shall
	relieve such indemnifying party of any liability to the indemnified
	party under this Section 1.6, but the omission so to deliver
	written notice to the indemnifying party will not relieve it of any
	liability that it may have to any indemnified party otherwise than
	under this Section 1.6.
	 
	(d)
	 
	If the
	indemnification provided for in Sections 1.6(a) and (b) is held by
	a court of competent jurisdiction to be unavailable to an
	indemnified party with respect to any loss, claim, damage or
	expense referred to herein, then the indemnifying party, in lieu of
	indemnifying such indemnified party hereunder, shall contribute to
	the amount paid or payable by such indemnified party as a result of
	such loss, claim, damage or expense in such proportion as is
	appropriate to reflect the relative fault of the indemnifying party
	on the one hand and of the indemnified party on the other in
	connection with the statements or omissions or alleged statements
	or omissions that resulted in such loss, liability, claim or
	expense as well as any other relevant equitable considerations. The
	relative fault of the indemnifying party and of the indemnified
	party shall be determined by reference to, among other things,
	whether the untrue or alleged untrue statement of a material fact
	relates to information supplied by the indemnifying party or by the
	indemnified party and the parties’ relative intent,
	knowledge, access to information and opportunity to correct or
	prevent such statement or omission. In no event shall any Investor
	be required to contribute an amount in excess of the net proceeds
	received by such Investor upon the sale of the Registrable
	Securities giving rise to such indemnification
	obligation.
	 
	(e)
	 
	The obligations of
	the Company and Investors under this Section 1.6 shall survive the
	completion of any offering of Registrable Securities in a
	registration statement under this Section 1, and
	otherwise.
	 
	 1.7
	 
	Reports
	Under Securities Exchange Act
	. With a view to making
	available the benefits of certain rules and regulations of the
	Commission, including Rule 144, that may at any time permit an
	Investor to sell securities of the Company to the public without
	registration or pursuant to a registration on Form S-1 or Form S-3,
	the Company agrees to:
	 
	(a)
	 
	make and keep
	public information available, as those terms are understood and
	defined in Rule 144, at all times after the closing of the Exchange
	Agreements;
	 
	(b)
	 
	take such action,
	including the voluntary registration of its Common Stock under
	Section 12 of the Exchange Act, as is necessary to enable the
	Investors to utilize Form S-1 for the sale of their Registrable
	Securities, such action to be taken as soon as practicable after
	the end of the fiscal year in which the registration statement is
	declared effective;
	 
	(c)
	 
	file with the
	Commission in a timely manner all reports and other documents
	required of the Company under the Securities Act and the Exchange
	Act; and
	 
	(d)
	 
	furnish to any
	Investor, so long as the Investor owns any Registrable Securities,
	forthwith upon request (i) a written statement by the Company that
	it has complied with the reporting requirements of Rule 144 the
	Securities Act and the Exchange Act (at any time after it has
	become subject to such reporting requirements), or that it
	qualifies as a registrant whose securities may be resold pursuant
	to Form S-1 or Form S-3 (at any time after it so qualifies), (ii) a
	copy of the most recent annual or quarterly report of the Company
	and such other reports and documents so filed by the Company, and
	(iii) such other information as may be reasonably requested in
	availing any Investor of any rule or regulation of the Commission
	that permits the selling of any such securities without
	registration or pursuant to such form.
	 
	 
	 
	 1.8
	 
	Transfer
	or Assignment of Registration Rights
	. The rights to cause
	the Company to register Registrable Securities pursuant to this
	Section 1 may be transferred or assigned, but only with all related
	obligations, by an Investor to a transferee or assignee;
	provided
	, (i) that prior to
	any transfer or assignment, the Company is furnished with written
	notice stating the name and address of such transferee or assignee
	and identifying the securities with respect to which such
	registration rights are being transferred or assigned, (ii) such
	transferee or assignee agrees in writing to be bound by and subject
	to the terms and conditions of this Agreement and (iii) such
	transfer or assignment shall be effective only if immediately
	following such transfer or assignment the further disposition of
	such securities by the transferee or assignee is restricted under
	the Securities Act.
	 
	2.
	 
	Legend
	.
	 
	2.1           Each
	certificate representing Shares held by the Investors shall be
	endorsed with the following legend:
	 
	“THE
	SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
	WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
	COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
	REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
	“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED
	OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
	UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
	FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
	REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
	APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF
	COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
	SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES
	ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN
	CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY
	SUCH SECURITIES.”
	 
	2.2           The
	legend set forth above shall be removed, and the Company shall
	issue a certificate without such legend to the transferee of the
	Shares represented thereby, if, unless otherwise required by state
	securities laws, (i) such Shares have been sold under an effective
	registration statement under the Securities Act, (ii) in connection
	with a sale, assignment or other transfer, such holder provides the
	Company with an opinion of counsel, reasonably acceptable to the
	Company, to the effect that such sale, assignment or transfer is
	being made pursuant to an exemption from the registration
	requirements of the Securities Act, or (iii) such holder provides
	the Company with reasonable assurance that the Shares are being
	sold, assigned or transferred pursuant to Rule 144 or Rule 144A
	under the Securities Act.
	 
	3.
	 
	Miscellaneous
	.
	 
	 3.1
	 
	Governing
	Law
	. The parties hereby agree that any dispute which may
	arise between them arising out of or in connection with this
	Agreement shall be adjudicated only before a federal court located
	in the State of New York and they hereby submit to the exclusive
	jurisdiction of the federal and state courts of the State of New
	York with respect to any action or legal proceeding commenced by
	any party, and irrevocably waive any objection they now or
	hereafter may have respecting the venue of any such action or
	proceeding brought in such a court or respecting the fact that such
	court is an inconvenient forum, relating to or arising out of this
	Agreement or any acts or omissions relating to the registration of
	the securities hereunder, and consent to the service of process in
	any such action or legal proceeding by means of registered or
	certified mail, return receipt requested, in care of the address
	set forth below or such other address as the undersigned shall
	furnish in writing to the other.
	 
	 3.2
	 
	WAIVER
	OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY
	JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
	PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT
	PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
	IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY
	 
	 
	 
	 3.3
	 
	Waivers
	and Amendments
	. This Agreement may be terminated and any
	term of this Agreement may be amended or waived (either generally
	or in a particular instance and either retroactively or
	prospectively) with the written consent of the Company and
	Investors holding at least a 60% of the Registrable Securities then
	outstanding (the “
	Majority Investors
	”).
	Notwithstanding the foregoing, additional parties may be added as
	Investors under this Agreement, and the definition of Registrable
	Securities expanded, with the written consent of the Company and
	the Majority Investors. No such amendment or waiver shall reduce
	the aforesaid percentage of the Registrable Securities, the holders
	of which are required to consent to any termination, amendment or
	waiver without the consent of the record holders of all of the
	Registrable Securities. Any termination, amendment or waiver
	effected in accordance with this Section 3.3 shall be binding upon
	each holder of Registrable Securities then outstanding, each future
	holder of all such Registrable Securities and the
	Company.
	 
	 3.4
	 
	Successors
	and Assigns
	. Except as otherwise expressly provided herein,
	the provisions of this Agreement shall inure to the benefit of, and
	be binding upon, the successors, assigns, heirs, executors and
	administrators of the parties hereto.
	 
	 3.5
	 
	Entire
	Agreement
	. This Agreement constitutes the full and entire
	understanding and agreement among the parties with regard to the
	subject matter hereof, and no party shall be liable or bound to any
	other party in any manner by any warranties, representations or
	covenants except as specifically set forth herein.
	 
	 3.6
	 
	Notices
	.
	All notices and other communications required or permitted under
	this Agreement shall be in writing and shall be delivered
	personally by hand or by overnight courier, mailed by United States
	first-class mail, postage prepaid, sent by facsimile or sent by
	electronic mail directed (a) if to an Investor, at such
	Investor’s address, facsimile number or electronic mail
	address set forth in the Company’s records, or at such other
	address, facsimile number or electronic mail address as such
	Investor may designate by ten (10) days’ advance written
	notice to the other parties hereto or (b) if to the Company, to its
	address, facsimile number or electronic mail address set forth on
	its signature page to this Agreement and directed to the attention
	of its President, or at such other address, facsimile number or
	electronic mail address as the Company may designate by ten (10)
	days’ advance written notice to the other parties hereto. All
	such notices and other communications shall be effective or deemed
	given upon delivery, on the date that is three (3) days following
	the date of mailing, upon confirmation of facsimile transfer or
	upon confirmation of electronic mail delivery.
	 
	 3.7
	 
	Interpretation
	.
	The words “include,” “includes” and
	“including” when used herein shall be deemed in each
	case to be followed by the words “without limitation.”
	The titles and subtitles used in this Agreement are used for
	convenience only and are not considered in construing or
	interpreting this Agreement.
	 
	 3.8
	 
	Severability
	.
	If one or more provisions of this Agreement are held to be
	unenforceable under applicable law, such provision shall be
	excluded from this Agreement, and the balance of the Agreement
	shall be interpreted as if such provision were so excluded, and
	shall be enforceable in accordance with its terms.
	 
	 3.9
	 
	Independent
	Nature of Investors’ Obligations and Rights
	. The
	obligations of each Investor hereunder are several and not joint
	with the obligations of any other Investor hereunder, and no
	Investor shall be responsible in any way for the performance of the
	obligations of any other Investor hereunder. Nothing contained
	herein or in any other agreement or document delivered at any
	closing, and no action taken by any Investor pursuant hereto or
	thereto, shall be deemed to constitute the Investors as a
	partnership, an association, a joint venture or any other kind of
	entity, or create a presumption that the Investors are in any way
	acting in concert with respect to such obligations or the
	transactions contemplated by this Agreement. Each Investor shall be
	entitled to protect and enforce its rights, including without
	limitation the rights arising out of this Agreement, and it shall
	not be necessary for any other Investor to be joined as an
	additional party in any proceeding for such purpose.
	 
	 3.10
	 
	Counterparts
	.
	This Agreement may be executed in any number of counterparts, each
	of which shall be an original, but all of which together shall
	constitute one instrument.
	 
	 3.11
	 
	Telecopy
	Execution and Delivery
	. A facsimile, telecopy or other
	reproduction of this Agreement may be executed by one or more
	parties hereto, and an executed copy of this Agreement may be
	delivered by one or more parties hereto by facsimile or similar
	electronic transmission device pursuant to which the signature of
	or on behalf of such party can be seen, and such execution and
	delivery shall be considered valid, binding and effective for all
	purposes. At the request of any party hereto, all parties hereto
	agree to execute an original of this Agreement as well as any
	facsimile, telecopy or other reproduction hereof.
	 
	[SIGNATURE PAGE FOLLOWS]
	 
	 
	IN
	WITNESS WHEREOF, the Company has caused this Agreement to be
	executed by its duly authorized officer, as of the date, month and
	year first set forth above.
	 
	MABVAX
	THERAPEUTICS HOLDINGS, INC.
	 
	 
	 
	By:________________________________
	Name:
	J. David Hansen
	Title:
	President and Chief Executive Officer
	 
	Address for
	notice
	:
	 
	MabVax
	Therapeutics Holdings, Inc.
	 
	Attention:  
	Chief Executive Officer
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	[COMPANY
	SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT]
	 
	 
	IN
	WITNESS WHEREOF, the undersigned Investor has executed this
	Agreement as of the date, month and year that such Investor became
	the owner of Registrable Securities.
	 
	 
	“Investor”
	 
	___________________________________
	 
	By:________________________________
	Name
	Title:
	 
	 
	 
	Address:
	 
	___________________________________
	 
	___________________________________
	 
	___________________________________
	 
	Telephone:__________________________
	 
	Facsimile:___________________________
	 
	Email:______________________________
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	[INVESTOR COUNTERPART SIGNATURE PAGE TO
	REGISTRATION RIGHTS AGREEMENT]
	 
	Annex A
	Plan of Distribution
	 
	Each
	selling stockholder of the common stock and any of their pledgees,
	assignees and successors-in-interest may, from time to time, sell
	any or all of their shares of common stock on the NASDAQ Capital
	Market or any other stock exchange, market or trading facility on
	which the shares are traded or in private transactions. These sales
	may be at fixed or negotiated prices. A selling stockholder may use
	any one or more of the following methods when selling
	shares:
	 
	●
	ordinary brokerage
	transactions and transactions in which the broker-dealer solicits
	purchasers;
 
 
	 
	●
	block trades in
	which the broker-dealer will attempt to sell the shares as agent
	but may position and resell a portion of the block as principal to
	facilitate the transaction;
 
 
	 
	●
	purchases by a
	broker-dealer as principal and resale by the broker-dealer for its
	account;
 
 
	 
	●
	an exchange
	distribution in accordance with the rules of the applicable
	exchange;
 
 
	 
	●
	privately
	negotiated transactions;
 
 
	 
	●
	settlement of short
	sales entered into after the effective date of the registration
	statement of which this prospectus is a part;
 
 
	 
	●
	broker-dealers may
	agree with the selling stockholders to sell a specified number of
	such shares at a stipulated price per share;
 
 
	 
	●
	through the writing
	or settlement of options or other hedging transactions, whether
	through an options exchange or otherwise;
 
 
	 
	●
	a combination of
	any such methods of sale; or
 
 
	 
	●
	any other method
	permitted pursuant to applicable law.
 
 
	 
	The
	selling stockholders may also sell shares under Rule 144 under the
	Securities Act of 1933, as amended, if available, rather than under
	this prospectus.
	 
	Broker-dealers
	engaged by the selling stockholders may arrange for other
	brokers-dealers to participate in sales. Broker-dealers may receive
	commissions or discounts from the selling stockholders (or, if any
	broker-dealer acts as agent for the purchaser of shares, from the
	purchaser) in amounts to be negotiated, but, except as set forth in
	a supplement to this prospectus, in the case of an agency
	transaction not in excess of a customary brokerage commission in
	compliance with FINRA Rule 2440; and in the case of a principal
	transaction a markup or markdown in compliance with FINRA
	IM-2440.
	 
	In
	connection with the sale of the common stock or interests therein,
	the selling stockholders may enter into hedging transactions with
	broker-dealers or other financial institutions, which may in turn
	engage in short sales of the common stock in the course of hedging
	the positions they assume. The selling stockholders may also sell
	shares of the common stock short and deliver these securities to
	close out their short positions, or loan or pledge the common stock
	to broker-dealers that in turn may sell these securities. The
	selling stockholders may also enter into option or other
	transactions with broker-dealers or other financial institutions or
	the creation of one or more derivative securities which require the
	delivery to such broker-dealer or other financial institution of
	shares offered by this prospectus, which shares such broker-dealer
	or other financial institution may resell pursuant to this
	prospectus (as supplemented or amended to reflect such
	transaction).
	 
	 
	 
	The
	selling stockholders and any broker-dealers or agents that are
	involved in selling the shares may be deemed to be
	“underwriters” within the meaning of the Securities Act
	of 1933, as amended, in connection with such sales. In such event,
	any commissions received by such broker-dealers or agents and any
	profit on the resale of the shares purchased by them may be deemed
	to be underwriting commissions or discounts under the Securities
	Act of 1933, as amended. Each selling stockholder has informed us
	that it does not have any written or oral agreement or
	understanding, directly or indirectly, with any person to
	distribute the common stock.
	 
	We are
	required to pay certain fees and expenses incurred by us incident
	to the registration of the shares. We have agreed to indemnify the
	selling stockholders against certain losses, claims, damages and
	liabilities, including liabilities under the Securities Act of
	1933, as amended.
	 
	Because
	selling stockholders may be deemed to be “underwriters”
	within the meaning of the Securities Act of 1933, as amended, they
	will be subject to the prospectus delivery requirements of the
	Securities Act of 1933, as amended, including Rule 172 thereunder.
	In addition, any securities covered by this prospectus which
	qualify for sale pursuant to Rule 144 under the Securities Act of
	1933, as amended may be sold under Rule 144 rather than under this
	prospectus. There is no underwriter or coordinating broker acting
	in connection with the proposed sale of the resale shares by the
	selling stockholders.
	 
	We
	agreed to keep this prospectus effective until the earlier of (i)
	the date on which the shares may be resold by the selling
	stockholders without registration and without the requirement to be
	in compliance with Rule 144(c)(1) and otherwise without restriction
	or limitation pursuant to Rule 144 or (ii) all of the shares have
	been sold pursuant to this prospectus or Rule 144 under the
	Securities Act or any other rule of similar effect. The resale
	shares will be sold only through registered or licensed brokers or
	dealers if required under applicable state securities laws. In
	addition, in certain states, the resale shares may not be sold
	unless they have been registered or qualified for sale in the
	applicable state or an exemption from the registration or
	qualification requirement is available and is complied
	with.
	 
	Under
	applicable rules and regulations under the Securities Exchange Act
	of 1934, as amended, any person engaged in the distribution of the
	resale shares may not simultaneously engage in market making
	activities with respect to the common stock for the applicable
	restricted period, as defined in Regulation M, prior to the
	commencement of the distribution. In addition, the selling
	stockholders will be subject to applicable provisions of the
	Securities Exchange Act of 1934, as amended, and the rules and
	regulations thereunder, including Regulation M, which may limit the
	timing of purchases and sales of shares of the common stock by the
	selling stockholders or any other person. We will make copies of
	this prospectus available to the selling stockholders and have
	informed them of the need to deliver a copy of this prospectus to
	each purchaser at or prior to the time of the sale (including by
	compliance with Rule 172 under the Securities Act of 1933, as
	amended).
	 
	 
	Annex
	B
	 
	 
	Selling Securityholder Notice and Questionnaire
	 
	The undersigned beneficial owner of common stock (the
	“
	Registrable
	Securities
	”) of MabVax
	Therapeutics Holdings, Inc., a Delaware corporation (the
	“
	Company
	”),
	understands that the Company has filed or intends to file with the
	Securities and Exchange Commission (the “
	Commission
	”)
	a registration statement (the “
	Registration
	Statement
	”) for the
	registration and resale under Rule 415 of the Securities Act of
	1933, as amended (the “
	Securities
	Act
	”), of the Registrable
	Securities, in accordance with the terms of the Registration Rights
	Agreement (the “
	Registration Rights
	Agreement
	”) to which this
	document is annexed. A copy of the Registration Rights Agreement is
	available from the Company upon request at the address set forth
	below. All capitalized terms not otherwise defined herein shall
	have the meanings ascribed thereto in the Registration Rights
	Agreement.
	 
	Certain legal consequences arise from being named as a selling
	securityholder in the Registration Statement and the related
	prospectus. Accordingly, holders and beneficial owners of
	Registrable Securities are advised to consult their own securities
	law counsel regarding the consequences of being named or not being
	named as a selling securityholder in the Registration Statement and
	the related prospectus.
	 
	NOTICE
	 
	The undersigned beneficial owner (the “
	Selling
	Securityholder
	”) of
	Registrable Securities hereby elects to include the Registrable
	Securities owned by it in the Registration
	Statement.
	 
	The undersigned hereby provides the following information to the
	Company and represents and warrants that such information is
	accurate:
	 
	QUESTIONNAIRE
	 
	 
	(a)
	            
	Full
	Legal Name of Selling Securityholder
 
 
	 
	(b)
	            
	Full
	Legal Name of Registered Holder (if not the same as (a) above)
	through which Registrable Securities are held:
 
 
	 
	(c)
	            
	Full
	Legal Name of Natural Control Person (which means a natural person
	who directly or indirectly alone or with others has power to vote
	or dispose of the securities covered by this
	Questionnaire):
 
 
	 
	2.
	            
	Address for Notices to Selling Securityholder:
 
 
	 
	 
| 
 
	Telephone:
 
 | 
| 
 
	Fax:
 
 | 
| 
 
	Contact Person:
 
 | 
 
	 
	 
	(a)
	            
	Are
	you a broker-dealer?
 
 
	 
	Yes
	                      
	No
	 
	(b)
	            
	If
	“yes” to Section 3(a), did you receive your Registrable
	Securities as compensation for investment banking services to the
	Company?
 
 
	 
	Yes
	                      
	No
	 
	 
	Note:
	                       
	If
	“no” to Section 3(b), the Commission’s staff has
	indicated that you should be identified as an underwriter in the
	Registration Statement.
 
 
	 
	(c)
	            
	Are
	you an affiliate of a broker-dealer?
 
 
	 
	Yes
	                      
	No
	 
	(d)
	            
	If
	you are an affiliate of a broker-dealer, do you certify that you
	purchased the Registrable Securities in the ordinary course of
	business, and at the time of the purchase of the Registrable
	Securities to be resold, you had no agreements or understandings,
	directly or indirectly, with any person to distribute the
	Registrable Securities?
 
 
	 
	Yes
	                      
	No
	 
	Note:
	                       
	If
	“no” to Section 3(d), the Commission’s staff has
	indicated that you should be identified as an underwriter in the
	Registration Statement.
 
 
	 
	4. Beneficial Ownership of Securities of the Company Owned by the
	Selling Securityholder.
	 
	Except as set forth below in this Item 4, the undersigned is not
	the beneficial or registered owner of any securities of the Company
	other than the securities issuable pursuant to the Exchange
	Agreements.
	 
	(a)
	            
	Type
	and Amount of other securities beneficially owned by the Selling
	Securityholder:
 
 
	 
	5. Relationships with the Company:
	 
	Except as set forth below, neither the undersigned nor any of its
	affiliates, officers, directors or principal equity holders (owners
	of 5% of more of the equity securities of the undersigned) has held
	any position or office or has had any other material relationship
	with the Company (or its predecessors or affiliates) during the
	past three years.
	 
	State any exceptions here:
	 
	 
	 
	 
	The undersigned agrees to promptly notify the Company of any
	inaccuracies or changes in the information provided herein that may
	occur subsequent to the date hereof at any time while the
	Registration Statement remains effective.
	 
	By signing below, the undersigned consents to the disclosure of the
	information contained herein in its answers to Items 1 through 5
	and the inclusion of such information in the Registration Statement
	and the related prospectus and any amendments or supplements
	thereto. The undersigned understands that such information will be
	relied upon by the Company in connection with the preparation or
	amendment of the Registration Statement and the related
	prospectus.
	 
	IN WITNESS WHEREOF the undersigned, by authority duly given, has
	caused this Notice and Questionnaire to be executed and delivered
	either in person or by its duly authorized agent.
	 
	Date:
	 
	Beneficial
	Owner:
	 
	By:_________________________________
	      Name:
	      Title:
	 
	[SIGNATURE PAGE FOR SELLING SECURITYHOLDER NOTICE AND
	QUESTIONNAIRE]